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Abstract 
Prodigiosins and tambjamines are natural compounds from bacterial and marine 
sources belonging to a family containing a common 4-methoxy-2,2'-bipyrrole core. 
These compounds have received a lot of interest due to their promising biological 
activities. Studies have suggested DNA as a potential therapeutic target for the 
natural prodigiosin and tambjamine due to their ability to facilitate oxidative DNA 
cleavage in the presence of Cu2+. Based on this we sought to study the metal 
binding activity of new prodigiosin and tambjamine analogues. A new prodigiosin 
analogue was synthesized and complexed with Cu2+. This revealed 1:1 complex 
formation between the tripyrrole and Cu2+ that was confirmed by mass spectra and 
NMR spectra analysis.  In addition in situ studies also revealed that our new 
analogues of prodigiosin cannot bind Zn2+ when the methoxy group on ring B is 
replaced by an alkyl group or when one of the ring nitrogens is methylated.   
Our UV-Vis experiments with calf thymus DNA showed that prodigiosins and 
tambjamines bind DNA mainly through an external mode, suggesting that 
hydrogen bonding between the pyrrole ring nitrogens and the bases of DNA takes 
precedence over stacking interactions. For the new Cu2+ complex synthesized 
however, we observed spectral changes that suggest intercalation into DNA.  
DNA cleavage experiments revealed that the prodigiosin-Cu complex is able to 
convert supercoiled DNA into its linear form. The data from the gel shift assays fit 
well to a first-order consecutive reaction model. In addition to preformed metal 
complexes, we showed DNA cleavage by in situ complexation of the ligands in the 
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presence of Cu2+. However, although we showed Zn2+ complex formation with 
prodigiosin analogues, in situ studies did not show induction of DNA cleavage by 
Zn2+ complexes under our experimental conditions. 
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1.0 Background  
 
Cancer is a major public health problem and there is great interest in the discovery 
and development of anticancer drugs as many current treatments, especially 
platinum based drugs, have toxicity problems1,2. As more research is carried out 
on the mechanisms of cancer tumorigenesis it has become clear that DNA is at 
the center of both the cause and treatment of cancer. DNA is the main driving force 
in tumorigenesis and also the main intracellular target in cancer chemotherapy3,4. 
The most common modes of action for most DNA-affecting antitumor agents are 
inhibition of DNA synthesis or DNA damage. Prodigiosins and tambjamines have 
been identified as new anticancer agents promoting apoptosis in a wide variety of 
human cancer cell lines such as gastrointestinal, breast and lung cancer cells, with 
no noticeable toxicity in nonmalignant cells5,6. This makes them candidate 
anticancer drugs. Ideally an anticancer drug should speciﬁcally target malignant 
cancer cells while having very little or no effect on non-malignant cells. 
 
1.1 Prodigiosins 
Bacteria produce a range of natural products that have been exploited for decades 
as pharmaceutically active compounds. One of these natural compounds, 
prodigiosin7, was first isolated and characterized in the 1930s and the structure 
elucidated in the 1960s8.  
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Prodigiosins are one of the best studied naturally occurring group of compounds 
isolated from bacteria including actinomycetes, Serratia spp., and Pseudomonas 
spp9, 10. These natural compounds are red-pigmented and the structure of 
prodigiosin is characterized by the three pyrrolic rings (ring A, B and C); existing in 
two interconverting forms: cis (or β) and trans (or α) as shown in Figure 1.  
(A) 
 
(B) 
            
Figure 1. (A) Canonical structure of prodigiosin, (B) Isomeric forms of prodigiosin. 
The balance between the isomeric forms is pH dependent with the trans isomer 
being more easily protonated. 
 
 
The representative members of the prodigiosin family shown in Figure 2 have the 
same pyrrolylpyrromethene skeleton with different alkyl substituents which may be 
linear but also often form rings or macrocycles. 
Although the physiological functions of prodigiosin in the producing organisms are 
not known; the natural prodigiosins (Figure 2) have been shown to have a variety 
of biological activities which include antibacterial, antimalarial, antifungal, 
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immunosuppressive, cytotoxic activities as well as involvement in surface 
adherence. Obatoclax, a prodigiosin analogue identified from a lead optimization 
of the compound streptorubin B has made its way into phase 1 and phase 2 clinical 
trials for the treatment of different types of cancers11. In addition to these biological 
activities there is a plethora of possible applications for prodigiosin that can be 
developed upon particularly as the library of analogues grows with the combined 
utilization of synthetic chemistry and biotechnological methods (figure 3) 9, 12.  
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Figure 2. Some members of the natural prodigiosin family: 1. Prodigiosin, 2. 
Undecylprodigiosin, 3. Metacycloprodigiosin, 4. Streptorubin B13. 
 
 
The prodigiosins have been shown to be able to induce apoptosis in rat 
hepatocellular and human breast cancer cell lines with very little effect on non-
cancerous cells9,10. The immunosuppressive properties of prodigiosins have been 
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shown in their ability to inhibit the blastogenesis of T cells as well as their ability to 
selectively suppress the T cell-dependent antibody response without damaging the 
lymphoid organs14,15 . The antimalarial activity of prodigiosins has also shown a lot 
of promise; metacycloprodigiosin isolated from the fermentation broth of 
Streptomyces spectabilis BCC 4785 was shown to have significant activity against 
P. falciparum and weaker cytotoxicity16. 
 
 
 
Figure 3. Synthesis and possible applications of prodigiosins; reproduced from 
reference9. 
 
A recent study carried out to show direct comparison of the antimalarial activity of 
prodigiosin, undecylprodiginine, metacycloprodiginine and streptorubin B showed 
that these compounds had potent antimalarial activity with very low IC50 values (8, 
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7.7, 1.7, and 7.8 nM, respectively) against P. falciparum strain D6 and were slightly 
more active than CQ (11 nM)17.  
There are multiple mechanisms of action that have been related to the biological 
activities of prodigiosins (figure 4). Some of these include disruption of intracellular 
pH gradients by H+/Cl- transport, inducing cell cycle arrest and facilitating oxidative 
DNA cleavage in the presence of Cu2+ 18,19,20. The ability of prodigiosins to damage 
DNA and change intracellular pH has led to their increased study in cancer 
research as these are some of the processes which can lead to the induction of 
apoptosis. In cells, prodigiosin has been detected in the nucleus, mitochondrial 
membrane, concentrated in the cytoplasm and also in granules located near the 
nucleus. 
The presence of prodigiosin in the nucleus is interesting as it shows that 
prodigiosins are able to reach DNA if that is the cellular target on which they act in 
their mechanism of action. In addition, it has been found that the biosynthetic 
cluster of S. maracescens is always flanked by genes encoding a copper-efflux 
pump (cueR and copA). Although the function of this pump is not known, it is 
possible that it provides a way of reducing Cu2+ concentrations in the cell to reduce 
cleavage of its own DNA during prodigiosin production9,21. 
 
 
6 
 
 
 
Figure 4. Some of the cellular processes affected by prodiginines; adapted from 
reference 22. 
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1.2 Tambjamines 
The tambjamines are also natural compounds isolated from bacteria and marine 
invertebrate animals. They are a group of alkaloids structurally closely related to 
prodigiosins and comprise two pyrrole rings with an enamine moiety at C-5 and a 
methoxy group at C-4. Most tambjamines have short alkyl chains substituted for 
the enamine nitrogen (figure 5).  
 
N
H N NH2
OMe
N
H N NH2
OMe
N
H N NH
OMe
Br
tambjamine A tambjamine Ctambjamine B
 
Figure 5. Structures of tambjamines A-C. 
 
The tambjamines have been implicated in chemical defense mechanisms of 
marine organisms against their predators. They possess a range of biological 
activities including antimicrobial, antitumour and immunosuppressive activities. 
The tambjamines have been shown to have antimicrobial activity against E. coli, 
Staphylococcus, B. subtilis, and Candida albicans22.  
Prodigiosins and tambjamines have been previously shown to interact with DNA. 
For some of the tambjamines their intercalation into DNA as well as their oxidative 
cleavage of single strand DNA has correlated well with their antitumor properties20, 
23,24,20, 25. Borah and co-workers have previously suggested that tambjamines 
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could potentially be developed as DNA probes and DNA targeting anticancer 
agents based on their ability to cause copper mediated DNA cleavage23,25. The 
DNA binding and nuclease activity of both prodigiosin and tambjamine compounds 
might explain some of their biological activities. 
There is increased interest and research in the medicinal use and application of 
metal complexes. The success of cisplatin has led to the search for other metal 
complexes with pharmacological activities. There are several platinum anticancer 
agents currently in use. In addition there are a variety of non-platinum containing 
pharmaceuticals in use as well. Metal complexes of prodigiosins and tambjamines 
will add to this growing library of metal complexes with pharmacological activities.   
This thesis reports my efforts to study the chemistry of prodigiosins and 
tambjamines, their metal binding ability as well as the effect of their metal 
complexes on their DNA binding modes and cleavage abilities. The prodigiosins 
and tambjamines possess pyrrolic nitrogens and are electron rich leading to 
various coordination abilities. The covalent attachment of prodigiosins and 
tambjamines to metals can yield complexes with novel DNA interactions that can 
influence biological activity. The metal complexes introduce new modes of binding 
to DNA not only through the change in geometry of the ligand when complexed 
with different metals, but also the ability of the complex to interact with DNA by 
both metal coordination and through intercalation of the attached ligand. The 
following chapters lay out the background and experimental approaches to this 
study followed by the specific aims of this Ph.D. thesis. 
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2.0 Introduction 
2.1 The structure of DNA 
The double helical structure of DNA was deduced over six decades ago by Watson 
and Crick using X-ray diffraction patterns of DNA to deduce information about the 
double helix. DNA is contained in the cell nucleus of eukaryotes where it is packed 
into chromosomes. The DNA occurs as a double helical molecule. The two strands 
that form the DNA helix run in opposite directions and are complementary to each 
other because the sequence on one strand determines the sequence on the 
opposite strand (figure 6). 
DNA contains two purine bases adenine (A) and guanine (G) and two pyrimidine 
bases cytosine (C) and thymine (T). In addition, DNA also contains a pentose, 2’-
deoxy-ribose which is covalently attached to a base to make a nucleoside.  When 
a phosphate group is attached to the nucleoside, a nucleotide is formed. The 
nucleotides are joined together covalently through phosphate group bridges in 
which the 5’ phosphate group of one nucleotide is joined to the 3’-OH group of the 
adjacent nucleotide forming a phosphodiester bond. 
The purines in DNA are weakly basic aromatic molecules. The purines are nearly 
planar and the pyrimidines are planar molecules. The bases in DNA stack together 
through hydrophobic interactions. These base stacking interactions help to 
stabilize the 3-dimensional structure of DNA. Purines and pyrimidines also 
possess functional groups; ring nitrogens, carbonyl groups and amino groups that 
are involved in hydrogen bonding. The two strands of DNA are joined by hydrogen 
10 
 
bonds formed between the bases. Two hydrogen bonds are formed between A-T 
pairs and 3 hydrogen bonds between G-C pairs. 
DNA can adopt a variety of conformations depending on its environment and 
primary structure. Forms A, B, C, D and Z have been identified, with form B being 
the most prominent (figure 7)26. 
 
 
Figure 6. DNA occurs in the nucleus packed into chromosomes. The two strands 
of DNA form the double helix which is made up of two strands held together by 
hydrogen bonds between A-T and G-C base pairs27. 
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Figure 7. Features of regular helical structures of A, B, C and Z DNA deduced 
from representative X‐ray fiber diffraction models26’ 28. In addition DNA can also 
occur in triplex (H-DNA), tetraplex (G- quadruplex DNA) and i-motif. These forms 
are possible due to unusual (Hoogsteen) base pairs29. 
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2.2 DNA Binding Modes 
There are 3 main modes of binding between DNA and small molecules: 
1. Intercalation 
This type of interaction can occur from either the major or minor groove and is 
stabilized by π interactions of the complexing molecule and nucleobases of DNA.  
Intercalation involves the insertion of a planar molecule between DNA base pairs, 
which results in a decrease in the DNA helical twist, cause DNA backbone 
distortion and lengthening of the DNA30.Intercalation results in an increase in 
separation of nucleobases that leads to a distortion in the helix. To make up for 
this distortion the DNA duplex can partially unwind. 
 
2. Groove binding 
Small molecules and metal complexes can interact with DNA through either the 
major or minor groove. The size, shape, charge and hydrogen bonding potential 
determines which groove the complex will access as well as whether the complex 
will react with the backbone or nucleobases. Some ruthenium derivatives that have 
strong hydrogen bonding potential have been shown to favor major groove 
binding31. 
 
3. Outside edge / electrostatic interactions. 
These involve ligands (metal ions) to the outside of the helix through electrostatic 
interactions with the sugar phosphate backbone. The association of positively 
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charged counter ions with the DNA polyanion has a large effect on DNA 
conformation and stability. 
 
Metal complexes interact with DNA through intercalation, groove binding and 
electrostatic interactions (figure 8). Intercalation and groove binding are the two 
most important binding modes when it comes to DNA damage.  
a.  b.   c.  
 
Figure 8. Binding modes of small molecules to DNA: a. intercalation, b. groove 
binding, c. outside edge/ electrostatic interactions. 
 
Groove binding, does not induce the large conformational changes in DNA that 
happen with intercalation. Groove binders are usually crescent-shaped molecules 
that bind to the minor groove of DNA and block DNA protein interactions30, 32. Both 
groove binding and intercalation can lead to anticancer and anti-bacterial 
properties of molecules, so drugs that bind DNA cannot be distinguished as groove 
binders or intercalators based solely on their pharmacological effects. The 
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intercalating ability of metal complexes has been shown to increase with increased 
planarity of the compounds and coordinate geometry of the ligand while the donor 
atom influences both binding mode and extent of binding to DNA33,34. There are 
several methods that can be used to determine whether mode of binding is 
intercalation or groove binding. One of the most commonly used methods is UV-
visible spectrophotometry. Molecules containing aromatic or phosphate 
chromophore groups can interact with the double helix structure of DNA, and this 
interaction can be observed as changes in the absorption spectra in the absence 
and presence of the small molecule. The changes are seen as red shift or blue 
shift as well as hyperchromic or hypochromic effects.  Hypochromicity at 260 nm, 
the maximum absorption of DNA, indicates the compaction of DNA due to the 
electrostatic interaction35. Intercalation lengthens the DNA helix as DNA base pairs 
undergo some separation in order to accommodate the small molecule inserting 
itself; this leads to hyperchromicity at 260 nm36. 
Viscosity studies can also be used to determine mode of binding. This is because 
viscosity is sensitive to the length of DNA and so this makes this method very 
sensitive for intercalators36. Other modes of binding do not result in lengthening of 
DNA. Groove binders and non-classical or partial intercalators can cause kinks 
(bends) in DNA, and this reduces the length of DNA36. 
Ligand binding to DNA can disrupt protein-DNA interactions and thus affect other 
important biological processes that occur as a result of successful protein-DNA 
interactions. We have a library of novel analogs of the natural prodigiosins and 
tambjamines which was synthesized in continuation of a drug discovery program 
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aimed at finding an efficient antimalarial agent. Most of these analogs exhibited 
enhanced antimalarial activity against chloroquine-sensitive (CQS) D6 and 
chloroquine-resistant (CQR) Dd2 and 7G8 strains of P. falciparum as well as 
improved toxicological profiles in human liver hepatocellular carcinoma cell line 
(HepG2)12. 
We are interested in the nature of complexes that these compounds form with Cu2+ 
and Zn2+ and their DNA binding activities, because there has been a lot of interest 
in transition metal complexes of small molecules as drug candidates or diagnostic 
agents. 
 
2.3 Supercoiled DNA and Small Molecule Interactions 
Supercoiled DNA can be used as a drug substrate for the detection of drug DNA 
interactions. Supercoiled DNA is also called SC or form I DNA, and DNA binding 
compounds can bind to this form of DNA and convert the SC DNA into an open 
circular (OC or form II) DNA. Many compounds that interact with and damage DNA 
show common features in their structure and effects; intercalators are usually 
planar and can lead to DNA strand breaks, while groove binders are crescent 
shaped and do not usually lead to lots of side effects (figure 9)30. 
16 
 
 
 
Figure 9. Structures of some intercalators and groove binders from reference37. 
 
Some of the earliest examples of metals and their compounds being used in 
medical applications date from as far back as 3000 BC, when the ancient 
Egyptians were using copper sulfate to sterilize the water used in their tonics and 
the Romans using zinc to promote wound healing. However, the use of metal-
based drugs was stopped largely due to their systemic toxicity and also 
development of newer drugs38. 
Over the last three decades, however, there has been renewed interest in the 
metal complexes as pharmaceuticals. Some of these are shown in Fig 10. Some 
of these metal containing compounds can act as nucleases and chemically modify 
SC DNA to OC DNA and further into a linear (LC or form III) DNA conformation. 
DNA is very stable to covalent bond cleavage and requires use of enzyme 
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nucleases for strand scission of the phosphodiester backbone to occur. The half-
life of DNA under physiological conditions has not been measured but had been 
extrapolated to 106 years39. As a result of this high hydrolytic stability, metal 
nucleases would need to promote strand scission by a high magnitude in order to 
facilitate the reaction40. Cisplatin, a clinical antitumor drug, has been shown to 
convert SC DNA to form II by promoting the alkylation of guanine bases41. 
 
 
 
Figure 10. Some metal complexes that have clinical uses42,43. 
 
Activated bleomycin (Fe2+BLM or Cu2+BLM) has been shown to interact with DNA 
very strongly and causes scission of the DNA through formation of reactive oxygen 
species (ROS)44. 
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2.4 DNA damage 
Damage to DNA can occur through different mechanisms, namely: 
1. Hydrolysis of phosphodiester bond 
2. Oxidation of nucleobases 
3. H- abstraction from ribose 
 
2.4.1 Hydrolytic DNA Cleavage 
The hydrolytic cleavage of DNA occurs in the presence of metal ions which act as 
Lewis acids. The Lewis acids can either activate the phosphate group, making it 
susceptible to nucleophilic attack, or alternatively the Lewis acid will activate H2O 
or OH- as nucleophile. The hydrolysis reaction occurs by a nucleophilic attack at 
the phosphate backbone to form a five-coordinate phosphate intermediate (figure 
11). This is followed by cleavage of either the 3' phosphate (common in enzymatic 
systems) or the 5'-phosphate, single strand scission and yielding R-OH and R-O-
PO3H2. 
 
Figure 11. Proposed mechanism for the hydrolytic cleavage of DNA. 
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2.4.2 Oxidative DNA cleavage 
Normal cellular metabolism is the major source of ROS (figure 12) The electron 
transport chain has the potential to leak electrons to oxygen resulting in superoxide 
generation45.  Cells are constantly exposed to ROS which are a result of processes 
occurring within the cells. Oxygen is vital in many biological processes but it can 
also lead to generation of ROS.  
 
Figure 12. Reactive oxygen species production in the mitochondria46. 
 
If the ROS are not removed, e.g. when antioxidants are depleted or the defenses 
cannot cope, the ROS will very often react with DNA, proteins and other 
components leading to undesirable effects i.e. single strand breaks, double strand 
breaks and chromosomal aberrations (Figure 13). 
Oxidative DNA cleavage is facilitated by reactive intermediates which are usually 
reduced oxygen species. The oxygen species are produced from redox reactions 
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with metal complexes and they react with the sugar moiety or with nucleobases 
leading to direct strand cleavage of labile strands in DNA.  
      
 
 
 
 
Figure 13. (A) Reactive oxygen species  at high concentrations place cells in a 
state of ‘oxidative stress’ and this causes damage to lipids, proteins and DNA47. 
different types of DNA damage48.  (B) Compounds that promote double strand 
DNA cleavage are cytotoxic because dsDNA damage is more difficult to repair 
than ssDNA damage. 
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Of the ROS, the highly reactive free radicals react with compounds by addition and 
abstraction, depending on the electron density at the site of addition or abstraction. 
The hydroxyl radical (•OH) is highly reactive and reacts by adding to the double 
bonds of heterocyclic DNA bases (figure 14) and by abstracting an H atom from 
the methyl (-CH3) group of thymine or C-H bonds of deoxyribose47’48  
 
Figure 14. The hydroxyl radical reacts with DNA bases (guanine and thymine) by 
adding to the double bond. 
 
Other types of products (figure 15) can be formed depending on whether oxygen 
is present or absent as well as other conditions. These products include DNA base 
damage products such as those from C-8 hydroxylation of guanine to form 8-oxo-
7,8-dehydro-2′-deoxyguanosine, hydroxymethyl urea, urea and thymine glycol47. 
One of the effects of  oxidative DNA damage is mutation of DNA, which can lead 
to carcinogenesis as well as alterations in transcription46.  
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Figure 15. Some DNA base damage products resulting from reactive oxygen 
species. 
 
2.5 Key Role of H2O2 in cells  
Hydrogen peroxide in the cells is produced mainly in mitochondria under conditions 
of metabolic stress from partial reduction of O2 leading to superoxide anion 
formation. Enzymes such as superoxide dismutase (SOD) catalyse the 
dismutation of superoxide radical to H2O2. Other enzymes such as monoamine 
oxidase and amino acid oxidase also lead to cellular H2O2 production49. In the cells 
concentration of H2O2 is determined by rate of formation of H2O by detoxifying 
enzymes catalase (CAT) and glutathione peroxide (GPx)50. 
In eukaryotes, H2O2 has been seen to have important roles as a signaling molecule 
in the regulation of a variety of biological processes. Cancer cells have been shown 
to have high cellular levels of this ROS and also produce high amounts of H2O251’52. 
The anticancer effect of various chemotherapeutic agents currently in use such as 
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paclitaxel and cisplatin can therefore be mediated, at least in part, by an increase 
in the cellular levels of H2O253. 
 
 
 
Figure 16. Pathways for generation of ROS production and detoxification54. 
 
2.6 Copper and Zinc in Biological Systems 
Copper and zinc are bioessential elements responsible for the function of many 
cellular enzymes and proteins. Both copper and zinc are found in various tissues 
and cellular compartments, and serum concentrations of both Cu2+ and Zn2+ have 
been reported to be between 15-20 µM55. 
Copper was first used by humans over 10,000 years ago. It belongs to group II 
metals of the periodic table with electronic configuration [Ar] 3d10 4s1. In biological 
systems, copper ions usually exist in two oxidation states; the cuprous (Cu+, 
reduced state) with electronic configuration [Ar] 3d10 and cupric (Cu2+, oxidized 
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state) with electronic configuration [Ar] 3d9. This redox nature of Cu allows for them 
to participate in electron transfer reactions56.  Copper is essential for the activities 
of several proteins such as Cu-Zn superoxide dismutase (Cu-Zn SOD), 
cytochrome oxidase as well as transcription factors57,58. High concentrations of Cu 
are toxic for both prokaryotic and eukaryotic cells59. The cupric ion (Cu2+) can be 
reduced to cuprous (Cu+) by reductants, e.g. ascorbic acid. The Cu+ formed is then 
able to facilitate formation of hydroxyl radicals (·OH) through the Fenton reaction 
by decomposition of H2O2. The redox reactions in which Cu participates can lead 
to formation of reactive oxygen species (ROS) which can potentially lead to 
damage to proteins, lipids and DNA. Attempts to establish how Cu complexes 
cause DNA damage or cleavage have mostly pointed to the likelihood of the 
involvement of hydroxyl radicals. This would happen through a Fenton-like 
process59, 60: 
 
LCu (II) + H2O2  → LCu (I) + ·OOH + H+ 
LCu (I) + H2O2 → LCu (II) + OH- + ·OH 
                                          
L= organic ligand       Scheme 1              
 
This suggestion was due to observed enhanced plasmid DNA cleavage in the 
presence of hydrogen peroxide (H2O2). The H2O2 forms the hydroxyl (·OH) radical 
which either oxidizes the bases of DNA or generates other radicals leading to DNA 
strand scission at the phosphodiester bonds. If the oxidative cleavage occurs at 
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the carbohydrate, abstraction of one hydrogen of deoxyribose (e.g C-3’ 
abstraction) can initiate the oxidative cleavage process (figure 17). 
Zinc occurs in the body as Zn2+, electronic configuration [Ar] 3d10. Zn2+ is the single 
stable oxidation state in solution and so it does not play a redox active role in 
biological processes but it is important for the functioning of numerous proteins, 
enzymes (e.g. RNA polymerases, alcohol dehydrogenase, carbonic anhydrase, 
and alkaline phosphatase) and transcription factors where it plays catalytic, 
structural or regulatory roles. 
 
 
 
Figure 17. Oxidative cleavage by C-3’ abstraction of deoxyribose 
 
Although Zn2+ does not participate in one-electron redox reactions under biological 
conditions, it has been suggested that it may cause DNA damage through a 
hydrolytic mechanism61. Studies with Zn2+ complexes of quercetin and polyamine 
macrocyclic ligands have shown that exposure of SC DNA to Zn2+ complexes 
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resulted in the disappearance of the SC DNA (Form I) accompanied by 
appearance of open-circular (Form II)61,62. Linearization of SC DNA by Zn2+ 
complexes has been observed only in experiments carried out over relatively long 
incubations (6-24 hours) at 37 °C61, 63. 
 
2.7 Specific Aims of This Proposal 
1. Syntheses and structure elucidation of Cu2+ and Zn2+ complexes of 
prodigiosin and tambjamine analogs. 
2. Determination of the binding properties of the prodigiosins and tambjamines 
and their metal complexes with DNA. 
3. Determination of the DNA cleavage activity of prodigiosins and 
tambjamines in the presence of metal ions. 
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3.0 Characterization, DNA Binding and Cleavage Activity of a new 
Metalloprodigiosin 
 
Introduction 
The family of red pigments called prodigiosins or prodiginines has been studied 
extensively due to their biological activities. Earlier studies focused on the activity 
of the natural prodigiosins, but more recently synthetic analogues with enhanced 
antimalarial activity have been developed17,64. These analogues were found to 
have  improved toxicological profiles, relative to chloroquine, in human liver 
hepatocellular carcinoma cell line (HepG2) as well as improved activity against 
chloroquine-sensitive, (D6) and chloroquine-resistant, (Dd2) and 7G8 strains of P. 
falciparum12,64. Functionalized C-ring prodigiosins have been shown to have 
improved antimalarial, chloride transport and DNA cleavage activity12,65. The 
prodigiosins also show anti-cancer activity which is thought to be due to a 
combination of their H+/Cl- transport and their ability to bind to DNA and cause 
copper-mediated double-strand DNA cleavage19,66. 
Transition metals play an important role in medicinal biochemistry. Metal 
containing compounds have been used to treat a variety of diseases or as 
diagnostic tools and also as anticancer agents67’68. The human body itself has 
metal-containing macromolecules that include iron (hemoglobin), molybdenum 
(xanthine oxidase), zinc (carbonic anhydrase, superoxide dismutase), and copper 
(hepatocuprein, superoxide dismutase). Interest in the use of metal complexes to 
treat disease was greatly increased after the success of cisplatin in cancer 
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treatment69. In addition to cisplatin, there are a variety of non-platinum containing 
pharmaceuticals in use containing metal ions such as zinc(II), copper(II), 
ruthenium and gold70,71. 
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Figure 18. Structure of prodigiosin, a prodigiosin·Cu complex and new prodigiosin 
analogues; 54 and 1. 
 
Prodigiosins have previously been shown to form complexes with copper and zinc 
and Park et al., reported the formation of a 1:1 square planar complex with an 
oxidized C-ring, formed by the reaction of prodigiosin and Cu2+ under basic 
conditions25. One analogue of prodigiosin, 54 (figure 18), was also shown to bind 
Cu2+ and Zn2+ although the Cu2+ complex could not be isolated72. Prodigiosin has 
also been shown to efficiently bind DNA and facilitate oxidative DNA cleavage in 
the presence of Cu(II). This DNA cleavage occurs without the need of an added 
reductant in a mechanism that is dependent on oxidation of the electron-rich 
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pyrrolylpyrromethene moiety66. In this work we investigated the interaction of a 
prodigiosin analogue, 1 (figure 18), with Cu2+ and showed that 1 forms a 
metalloprodigiosin complex (1·Cu) which is oxidized on the C-pyrrole ring and is 
able to bind to and cleave DNA.  
 
Experimental 
Synthesis of 1 
The synthesis of 1 was achieved through acid-catalyzed condensation of 
commercially available 3-ethyl-2,4-dimethylpyrrole with a bipyrrole (Scheme 2 
below). The bipyrrole was synthesized from Suzuki cross coupling between bromo 
pyrrole enamine (synthone 1) and Boc-pyrrole boronic acid under reflux, yielding 
the bipyrrole aldehyde (synthone 2)12,73. 
appropriate pyrrole 
        
 methanolic 2 N HCl
   MeOH,  rt,  5 h
N
HO
OMe
HCON(C2H5)2
POBr3 , CHCl3
0-60 oC, 5 h, 72%
Br
N
OMe
N
N
H
OMe
H
O
N
H
i) Pd(PPh3)4, N-Boc-2-pyrroleboronicacid
dioxane/H2O, Na2CO3, 100 
oC, 3 h
ii) LiOH, THF-MeOH, rt, 30 min, 76%
N
OMe
NH
HN
R3
R2
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R1-R3 = alkyl(aryl) substituents
Prodiginines
synthone 1
synthone 2
 
Scheme 2. Synthesis of prodiginine analogues. For 1, R1= CH3, R2= CH2CH3, R3= 
CH3.  
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Synthesis of the Cu2+ complex 
The metalloprodigiosin was synthesized as previousy described25. To a red 
solution of prodigiosin analogue, 1, (25 mg, 0.1 mmol) in tertiary butanol, 3 
equivalents of potassium tert-butoxide (35 mg, 0.3 mmol) in tertiary butanol were 
added, and then added a DMSO solution (2 equivalents) of CuCl2·2H2O (35 mg, 
0.2 mmol). The solution was stirred for 3-4 hours at room temperature and then 
concentrated under diminished pressure. The solid was extracted with ethyl ether 
to give a dark purple solution, washed with pentane and dissolved in ethyl acetate. 
The resulting purple colored complex (1·Cu) was characterized by ESI-MS and 
1H-NMR. 
 
DNA 
Calf thymus DNA (CT-DNA) was purchased from Sigma Aldrich chemicals, USA 
and prepared by dissolving 1 mg in 2 ml of buffer (4 mM sodium phosphate, 50 
mM NaCl, pH 7.8) overnight before use. The purity of CT-DNA was determined by 
monitoring UV absorbance at 260 nm and 280 nm. The A260/A280 ratio was found 
to be between 1.8 - 1.9, suggesting that the sample was sufficiently free from 
protein impurities74. DNA concentration was determined by UV spectrophotometry 
using ε = 6600 Mcm-1 at 260 nm.  
Plasmid DNA was prepared from transformation of E. coli Mach1 cells (Life 
Technologies) with pUC19 DNA. The cells were grown in Luria–Bertani medium 
for 12-16h. Plasmid DNA was then purified using a modified protocol of a 
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commercially available Omega-Biotek E.Z.N.A plasmid purification kit as 
described by Carbone et al75. The purification of plasmid DNA with this method 
ensured isolation of almost 100% of the plasmids in supercoiled form. 
 
DNA binding activity 
Absorption titration experiments were performed on 1·Cu complex (80 µM) in 4 
mM sodium phosphate buffer, 50 mM NaCl, pH 7.8 while varying concentrations 
of the CT-DNA (0-80 µM). Spectra were recorded on a Shimadzu 1700 UV-visible 
spectrophotometer using 1cm quartz cuvettes. The binding constant, (Kb) was 
determined from the ratio of the slope to the intercept from a plot of [DNA]/(εa-εf) 
vs [DNA]; where: εa is the apparent extinction coefficient calculated by Aobsd/[Cu] 
and εf is the extinction coefficient of the free (unbound) complex determined using 
a calibration curve of an isolated 1·Cu complex, with the Beer–Lambert law76. 
 
DNA cleavage 
Concentration dependent cleavage of pUC19 DNA 
Agarose gel electrophoresis experiments were performed with pUC19 DNA in 4 
mM sodium phosphate buffer, 50 mM NaCl, pH 7.8. DNA was incubated with 1·Cu 
in the presence and absence of H2O2 at 37°C for 1 hr. The reaction was quenched 
by adding 3 µL loading buffer (0.03% bromophenol blue, 0.03% xylene cyanol FF, 
60% glycerol, 60 mM EDTA). The samples were electrophoresed at 70V for 1.5 hr 
on a 0.8% agarose gel using tris-acetate-EDTA (TAE) buffer then stained with 
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ethidium bromide. DNA cleavage was visualized using the Typhoon Trio+ variable 
mode Imager (GE Healthcare) to measure the different isomers of pDNA. 
 
Assesment of DNA cleavage in the presence of antioxidants 
Plasmid DNA in 4 mM sodium phosphate buffer, 50 mM NaCl, pH 7.8 was 
incubated with 1·Cu in the presence of different antioxidants:  NaN
3
, DMSO, EDTA, 
CAT and SOD at 37°C for 1 hr. The reaction was quenched by adding 3 µL loading 
buffer (0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM 
EDTA). The samples were electrophoresed at 70V for 1.5 hr on a 0.8% agarose 
gel using tris-acetate-EDTA (TAE) buffer then stained with ethidium bromide. DNA 
cleavage was visualized using the Typhoon Trio+ variable mode Imager (GE 
Healthcare). 
 
Results 
UV-Vis titration and MS analysis  
In order to establish if the prodigiosin analogue, 1, interacts with Cu2+ a UV-Vis 
titration was carried out with 20 µM 1 adding 0.1 equivalents of Cu(OAc)2 every 10 
mins at room temperature in MeOH containing 10 mM tert-butoxide/acetic acid, pH 
10. Figure 19 shows a concentration dependent disappearance of the absorbance 
of free analogue 1 at 470 nm with concurrent gain of absorbance at 550-600 nm 
suggesting formation of 1·Cu complex. 
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Figure 19. UV-vis analysis of a titration of 1, 20 µM vs Cu(OAc)2 0.1-1.0 
equivalents. 
 
To confirm formation of a complex, the titration was repeated in a 90% methanol 
solution. The t-butoxide was omitted in these experiments to allow for subsequent 
mass spectrometric analysis. The red solution of 1 turned purple on addition of 
Cu(OAc)2 (figure 20 top panel) and MS analysis of the resulting solution revealed 
a peak at m/z = 355.07 suggesting formation of a Cu complex with the possible 
structure shown in figure 20 below: 
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Figure 20. The color change observed when Cu(OAc)2 is added to a solution of 1 
(top panel). ESI-MS analysis of 1·Cu complex formation in 90% MeOH solution 
(bottom panel). 
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Characterization of 1·Cu complex 
The 1·Cu complex was prepared as previously described and further analyses 
were conducted without additional purifications owing to complications with 
purification methods. The progress of the reaction was monitored by UV-Vis and 
TLC (figure 21). Since both 1 and 1·Cu are colored red and purple respectively; 
they were observed directly on the TLC plate. Furthermore, MS and 1H NMR 
studies and side by side comparison with 1 were carried out to elucidate the 
structure of 1·Cu complex (Figure 22, and 23). (Figure 21, top panel).   
 
A             B 
         
Figure 21. UV-Vis profile of 1 λmax 535nm and 1·Cu λmax 596nm (A) and TLC 
characterization of 1 and 1·Cu (40:60; Ethyl acetate:hexanes) (B). 
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The high resolution mass spectrum showed a molecular ion peak at 355.0731 [M]+ 
and this molecular ion is very similar to the calculated mass (355. 0740) that 
unambiguously suggests the formation of Cu complex with prodiginine 1 (figure 
22). The isotopes of Cu; 63Cu and 65Cu occur naturally at approximately 70:30 
abundance which are apparent in the observed MS isotope pattern. The MS data 
suggests formation of 1:1 1·Cu complex and this is consistent with what was 
previously reported for prodigiosin77.  
 
Figure 22. ESI-MS analysis of 1·Cu complex (top panel) and a comparison of the 
MS isotope patterns on 1·Cu with isotope simulation (bottom panel).  
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NMR characterization of 1·Cu was carried out on a 400MHz NMR spectrometer. 
A comparison of the proton NMR spectra for 1 with that of 1·Cu reveals that 1 has 
five aromatic protons with chemical shift δ 6 - 7.3 ppm, while 1·Cu shows seven 
aromatic protons with chemical shift δ 5.0 – 7.0 ppm range corresponding to the 7 
aromatic protons expected in 1·Cu.  
One of the significant differences in the 1H NMR spectra of 1 and 1·Cu is the 
appearance of two extra olefinic singlets at 5.03 and 5.13 ppm in addition to the 
five aromatic protons in 1·Cu (Figure 22).  These olefinic protons are characteristic 
to the exocyclic olefinic bond as in the 1·Cu complex. The rest of the five aromatic 
protons appear in the aromatic region, with exception of one proton that merged 
with one of the exocyclic olefinic protons. 
The methoxy group on the middle pyrrole ring is significantly shifted to the upfield 
region. Since the Cu2+ is paramagnetic, this causes poor resolution of the spectra 
such that most of the aromatic and aliphatic protons appear as broad singlets. 
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Figure 23. 1H NMR spectral (400 MHz, CDCl3) analysis. Top panel represents the 
1H NMR of prodigiosin analogue, 1, middle panel represents the 1H NMR of the 
complex 1·Cu, and bottom panel represents the expansion of olefinic and aromatic 
regions of 1·Cu. 
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1·Cu complex is reversible 
An EDTA chelation experiment showed that the 1·Cu complex formed is reversible 
(Figure 24). In the presence of excess EDTA there is a loss in absorbance of 1·Cu 
complex at 600 nm accompanied by an increase in absorbance at about 500 nm. 
Spectral changes in the absorbance of the 1·Cu complex were observed within the 
first minute of EDTA addition with disappearance of the peak at about 600 nm. 
There was a gradual increase in absorption at about 500 nm over time. This 
observation suggests that the 1·Cu complex is reversible and immediately forms 
a complex with EDTA. However, the fact that we do observe the ternary 1·Cu-
EDTA complex by mass spectrometry, after several minutes, suggests that the 
1·Cu complex is quite stable as EDTA does not immediately chelate the Cu2+ from 
the complex. The gradual appearance of a new peak at 500nm over an hour 
suggests that the dissociation of the 1* from the 1·Cu-EDTA complex occurs at a 
much slower rate than the formation of the 1·Cu-EDTA complex. In addition, the 
free 1* has a maximum absorbance at 500 nm, while the parent 1 compound 
absorbs at 535 nm. This observation suggests that there is a change in the 
structure of the parent ligand when it forms a complex with Cu2+, consistent with 
the NMR analysis, and although EDTA chelates Cu2+ it does not revert back to the 
original structure. 
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Figure 24. Spectral changes observed in the UV-Vis spectrum of 100 µM 1·Cu on 
addition of excess EDTA over 75 mins at room temperature. 
 
The formation of this complex was confirmed by ESI-MS characterization of the 
chelation process (figure 25). The data from the MS experiment shows that the 
EDTA forms a complex with the 1·Cu with a m/z of 689 which then dissociates into 
EDTA-Cu and free hydroxylated or methoxylated 1* (m/z 311 and 325) (figure 26). 
This is further evidence in support of the oxidation of the C-ring of prodigiosins 
during complex formation.   
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Figure 25. ESI-MS analysis of Cu2+ chelation from 1·Cu by EDTA; time=0 min (top 
panel), time=5 min (middle panel) and time=60 min (bottom panel). 
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Figure 26. ESI-MS analysis revealed that EDTA chelates Cu2+ from 1·Cu complex 
through a mechanism involving formation of a 1·Cu -EDTA intermediate before 
releasing free 1* and EDTA-Cu. 
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DNA Binding Studies 
To determine if the free prodigisoin analogue, 1, and the copper complex 1·Cu 
interact with DNA; a fixed concentration of the analogue or the Cu2+ complex was 
incubated with varying concentrations of CT-DNA for 1 hour at 37°C. 
Hyperchromism of about 28% was observed in the absorbance of 1 when 
incubated with increasing concentrations (0-80 µM) of CT-DNA in the absence of 
metal ion and 9% hyperchromism in the presence of Zn2+ (Figure 27). The extent 
of hyperchromism is indicative of partial or non-intercalative binding modes, such 
as electrostatic forces between the Cu2+ and the negatively charged phosphate 
groups on the DNA backbone, van der Waals interaction or hydrogen bonds. Since 
1 is assumed to be planar, it would be expected to intercalate between the base 
pairs of DNA. However, the data does not support this mode of interaction. It is 
possible that hydrogen bonding is a more favorable interaction, because DNA 
possesses several hydrogen bonding sites which are accessible, and 1 possesses 
amine (NH) groups in the pyrrole rings which can interact with the hydrogen 
bonding sites on CT-DNA. 
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Figure 27. Interaction of 1 with CT-DNA results in an increase in absorption of the 
prodigiosin analogue in the absence (top panel) and presence of Zn2+ and a 
decrease in the absorption of 1·Cu complex (middle panel) with increasing CT-
DNA (0-80µM). Inset: Plot of [DNA]/(εa-εf) vs [DNA] for the interaction of 1·Cu with 
DNA. 
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In the experiment with 1·Cu increasing the concentration of CT-DNA resulted in 
hypochromism of about 76% at 80 µM CT-DNA with no change in maximum 
absorption wavelength (Figure 27). These spectral shifts suggest that the 1·Cu 
complex binds to DNA by a stacking interaction mode. Intercalative mode involves 
stacking interactions between the complex and the base pairs of DNA. The π* 
orbital of the copper complex is partially filled by electrons from the π orbitals of 
the DNA bases, resulting in a decrease in transitions in the complex which leads 
to the observed hypochromism78. 
The binding constant was determined from the plot of [DNA]/(εa-εf) vs [DNA] 
(Figure 27 inset), using the absorption at 600 nm. The calculated Kb value for the 
1·Cu complex is 4.1 X 106 M-1. This Kb is of the same order as that reported for 
ethidium bromide, a  classical intercalator which has a Kb  value of 1.4 X 106 M-1 
suggesting that 1·Cu also strongly binds to CT-DNA by intercalation79.  
 
DNA Cleavage 
The DNA cleavage ability of 1 in the presence of Cu2+ and 1·Cu was determined 
by gel electrophoresis after a 1-hour incubation at 37°C. As shown in Figure 28, at 
concentrations above 500 nM, 1 begins to show DNA nuclease activity which is 
dependent on the presence of both Cu2+ and H2O2, as absence of either of these 
eliminates the ability of 1 to cleave DNA (Figure 29). The copper complex, 1·Cu 
also exhibits DNA nuclease activity and converts supercoiled (form I) DNA into 
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linear (form III) DNA (20-60%) in a concentration dependent manner at 40 – 200 
µM 1·Cu (figure 29). The nuclease activity does not occur when DNA is incubated 
with either preformed 1·Cu or 1+Cu alone (Figure 29 lanes 6-8). 
pUC19 + + + + + + + + 
1 - 50 nM 100 nM 300 nM 500 nM 1 µM 2.5 µM 5 µM 
Cu2+ - + + + + + + + 
H2O2 - + + + + + + + 
 
 
 
 
 
 
Figure 28. Gel shift analysis showing cleavage of 8.5 nM pUC19 DNA in the 
presence of 1 and added equimolar Cu2+ and 25 µM H2O2 at 37°C. 
 
pUC19 + + + + + + + + 
1·Cu - - 40 µM 200 µM 400 µM 400 µM - - 
1 - - - - - - 400 µM 400 µM 
H2O2 - + + + + - + - 
     
Figure 29. Gel shift analysis showing cleavage of 8.5 nM pUC19 DNA in the 
presence of 1·Cu at 37 °C.  
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In order to gain some insight into the mechanism of the DNA cleavage activity of 
µM 1·Cu a gel shift assay was carried out in the presence of NaN
3
, a singlet oxygen 
quencher; DMSO, a hydroxyl radical scavenger; EDTA, a metal chelator; catalase 
(CAT), a H2O2 decomposer, and SOD, a superoxide anion scavenger (Figure 30). 
The addition of EDTA and CAT provides a protective effect against cleavage 
activity of 1·Cu confirming the participation of the Cu2+ (as well as the H2O2) in the 
cleavage of DNA. However, NaN
3
, DMSO, and CAT do not protect DNA against 
cleavage suggesting that the mechanism of DNA cleavage might involve a 
shortlived hydroxyl radical (figure 31, Path A). Alternatively, 1·Cu might form a Pg–
Cu–OOH complex able to cause the DNA damage directly by attack on the 
phosphate group (Figure 31, Path B). 
 
pUC19 + + + + + + + + 
1·Cu - - 40 µM 40 µM 40 µM 40 µM - - 
H2O2 + + + + + - + - 
   NaN3 DMSO EDTA CAT SOD  
 
 
 
 
Figure 30. Gel shift analysis showing cleavage of 300 ng (8.5 nM) pUC19 DNA in 
the presence of 1·Cu + H2O2 at 37 °C.  
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Figure 31. Proposed mechanism for DNA cleavage by 1·Cu can involves 
formation of a Pg-Cu-OOH complex that leads to formation of ·OH radical (Path A) 
or nucleophilic attack of phosphate group (Path B). 
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Conclusion 
In this work, a new metalloprodigiosin, 1·Cu, was synthesized and the resulting 
complex characterized by various methods. The DNA binding and cleavage activity 
of the copper complex has been evaluated. Although the prodigisin analogue, 1, 
interacts with DNA, it did not have DNA cleavage activity in the absence of Cu2+. 
NMR analysis of the copper complex shows the presence of a vinylic group. 
Previous studies of metalloprodigiosins have shown this group to be on C-1 of the 
C-pyrrole ring of the complex, suggesting oxidation of the C-ring occurs during 
complex formation followed by dehydration to form the vinyl group25. The ESI-MS 
data also suggests formation of a 1:1 complex, and UV experiments and gel 
electrophoresis suggests that 1·Cu interacts with DNA through intercalation and in 
addition has DNA nuclease activity, causing double strand cleavage of supercoiled 
plasmid DNA in the presence of H2O2. Finally, we observed that the free analogue 
1 interacts with DNA through a non-intercalative binding mode, possibly hydrogen 
bonding. 
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4.0  In situ Studies of Cu2+ and Zn2+ Complexes of Prodiginine and 
Tambjamine Analogues; DNA Binding and Cleavage Activity. 
 
Introduction 
There has been increasing interest in the coordination chemistry of prodigiosins in 
an effort to explain their mechanism of action. In the previous chapter a new 
metalloprodigiosin, 1·Cu, was synthesized and shown to bind and cleave DNA in 
the presence of H2O2.  Prodigiosins (Pg) and tambjamines (Tm) have been shown 
to form complexes of Cu2+ while being oxidized in the process, and the complexes 
formed causing oxidative cleavage of DNA23,80,66. This ability of prodigiosins and 
tambjamines to act as chemical nucleases can explain some of their biological 
activities. 
Previous research has shown that natural prodigiosins as well as prodigiosin 
analogues designed with enhanced metal coordinating abilities bind Cu2+ to form 
complexes with a slightly distorted square planar geometry and Zn2+ to form 
complexes with tetrahedral geometry25,81. Square planar complexes containing 
aromatic moieties normally bind DNA by intercalation while octahedral and 
tetrahedral complexes are unsuitable for intercalation, and normally bind 
externally82,83.  
In this chapter we set out to look at several properties; pKa, Cu2+, and Zn2+ binding 
ability of Pg and Tm analogues, as well as DNA binding and cleavage activity, in 
order to determine if any of these properties correlate with biological activity.  
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Figure 32. A natural prodigiosin (red 2) and prodigisoin and tambjamine analogues 
(1-10) used in the study. 
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Experimental 
Synthesis of Prodiginine and Tambjamine Analogues 
 
Scheme 3. Synthesis of prodigiosin and tambjamine analogues. 
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Determination of pKa 
The pKa was determined in a wide range buffer series (Carmodys buffers). The 
buffers were prepared by mixing predetermined volumes of stock buffer solutions 
(solution A: 0.2 M boric acid; 0.05 M citric acid; solution B: 0.1 M tertiary sodium 
phospshate) to make solutions with pH ranging from 2.5 – 10.5. The Pg and Tm 
analogues were added to 200 µL of buffer to a final concentration of 50 µM and 
spectra were recorded on a Shimadzu 1700 UV-visible spectrophotometer using 1 
cm quartz cuvettes.  
Mass Spectroscopy Characterization 
Equimolar amounts of Cu(OAc)2 or Zn(OAc)2 were added to solutions of Pg or Tm 
in 90% methanol. The solutions were allowed to mix for an hour before Mass 
spectra were recorded on a ThermoElectron LTQ-Orbitrap high resolution mass 
spectrometer. 
DNA 
Calf thymus DNA (CT-DNA) was purchased from Sigma Aldrich chemicals, USA 
and prepared by dissolving 1mg in 2 ml of buffer (4 mM sodium phosphate, 50 mM 
NaCl, pH 7.8) overnight before use. The purity of CT-DNA was determined by 
monitoring UV absorbance at 260 nm and 280 nm. The A260/A280 ratio was found 
to be between 1.8 - 1.9 suggesting that the sample was sufficiently free from 
protein impurities74. DNA concentration was determined by UV spectrophotometry 
using ε = 6600 Mcm-1 at 260 nm.  
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Plasmid DNA was prepared from transformation of E. coli Mach1 cells (Life 
Technologies) with pUC19 DNA. The cells were grown in Luria–Bertani medium 
for 12-16 h. Plasmid DNA was then purified at 4°C using Omega-Biotek E.Z.N.A 
plasmid purification kit. The purification of plasmid DNA at low temperature 
ensured isolation of almost 100% of the plasmids in supercoiled form75. 
DNA binding activity 
Absorption titration experiments were performed on Pg and Tm analogues (20 µM) 
in 4 mM sodium phosphate buffer, 50 mM NaCl, pH 7.8 while varying 
concentrations of the CT-DNA (0-80 µM). Spectra were recorded on a Shimadzu 
1700 UV-visible spectrophotometer using 1 cm quartz cuvettes. 
 
DNA cleavage 
Concentration dependent cleavage of pUC19 DNA 
Agarose gel electrophoresis experiments were performed with pUC19 DNA as 
previously described. The reaction was quenched by adding 3 µL loading buffer 
(0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM EDTA). 
The samples were electrophoresed at 70 V for 1.5 hr on a 0.8% agarose gel using 
tris-acetate-EDTA (TAE) buffer then stained with ethidium bromide. DNA cleavage 
was visualized using the Typhoon Trio+ variable mode Imager, GE Healthcare, to 
measure the different isomers of pDNA. 
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Results 
Spectrophotometric determination of pKa 
The acid-base dissociation constant (pKa) of a drug is a key property influencing 
lipophilicity, solubility, protein binding and permeability. Knowledge of the pKa 
helps in understanding the ionic form a molecule will take across a range of pH 
values. This is important in physiological systems where ionization state will affect 
the rate at which the compound is able to diffuse across membranes. In this study, 
we recorded UV-Vis spectra of the Pg and Tm analogues in different pH buffers 
(pH 2.5-10). The absorption spectra of the compounds changes with pH to reflect 
the ratio of neutral to ionized species. Data from the first derivative plot was used 
to determine pKa values for the Pg and Tm analogues.  
  
Figure 33. Representative UV-Vis absorbance spectra for prodigiosin analogue as 
a function of pH (left panel) and the first derivative plot of change in absorbance 
as a function of pH showing the experimental pKas(right panel). 
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In this plot the largest change in absorbance occurs at the pH corresponding to a 
pKa and appears as a peak in the first derivative plot. The first derivative plot of the 
ratio of change in pH and change in absorbance vs pH shown in the representative 
figure 33. 
 
Table 1. Experimental pKa values of prodigiosin and tambjamine analogues 
 Ring A Ring B Ring C pKa1 pKa2 pKa3 pKa4 
Red 2 Pyrrole -OMe C11H23 3.50 5.30 7.80  
1 Pyrrole -OMe Me,Et,Me 3.45  5.48 8.06  
2 Pyrrole -OMe Me-PhCl, Me-
PhCl 
4.0 5.70 7.80  
3 Pyrrole Et  C11H23 3.40 5.20 7.70  
4 Pyrrole Me, Et Me,Et,Me 3.50 5.28 7.83  
5 N-Me, 
pyrrole 
-OMe Me-PhCl, Me-
PhCl 
4.20 6.0 7.90  
6 N-Me, 
Pyrrole 
-OMe C9H20OH 3.55 4.41 5.84 7.91 
7 Pyrrole -OMe adamantyl 4.0 5.70 8.30  
8 Et-pyrrole Et, Et adamantyl 3.70 4.80 6.90  
9 Et-Pyrrole Me, Et hexanoyl 3.80 4.40 7.50  
10 pyrrole No ring adamantyl 3.50 5.30 7.80  
 
As seen in table 1, there are very small differences between the pKa values despite 
the differences in substituents on the rings. Because of this, at physiological pH, 
the differences would not be significant in terms of how much of the analogue is 
protonated. 
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Mass Spectral Analysis of Cu2+ and Zn2+ complexes in solution 
Synthesis of stable Cu2+ and Zn2+ complexes of the rest of the prodigiosin and 
tambjamine analogues selected for use in this study proved difficult as the 
complexes formed were not stable enough to isolate. In light of this observation, 
formation of Cu2+ and Zn2+ complexes of Pg and Tm analogues was monitored by 
ESI-MS in 90% methanol (figures 34-39). Complexes of Cu2+ and Zn2+ can easily 
be recognized in the mass spectrum by their isotope patterns: (63Cu: 65Cu; 70;30) 
and (64Zn:66Zn:67Zn:68Zn; 49:28:4:19). 
The ESI-MS of red2·Cu showed m/z of 453.18 and 455.18 (100:44) consistent 
with the isotope ratios of Cu2+. The proposed structure of the complex is similar to 
other previously described PgCu complexes with an oxidized C-ring. In addition, 
we observed formation of a copper (II) complex with a methoxylated C-ring under 
our assay conditions (figure 34).   
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Figure 34. Mass spectra showing formation of Red2·Cu complex and isotope (top 
panel) and Red2-Zn complex (bottom panel) in 90% MeOH. 
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Figure 35. Mass spectra showing in situ formation of 1·Cu complex (top panel) 
and 1·Zn complex (bottom panel) in 90% MeOH. 
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In the previous chapter we isolated 1·Cu and confirmed the structure by ESI-MS 
and NMR. Figure 35 shows the mass spectra obtained from 1 and CuCl2 complex 
formation in 90% MeOH. The spectra show peaks with m/z values consistent with 
formation of Cu2+ and Zn2+ complexes in solution. The peaks observed for the Cu 
complex (m/z 355.07 and 357.07) and Zn complex (m/z 357.08, 359.08 and 
361.08) are consistent with the isotope pattern expected for Cu and Zn 
respectively. 
 
 
Figure 36. ESI-MS showing formation of 2·Cu complex in 90% MeOH 
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Analogues 3, 4 and 5 showed formation of Cu2+ complexes with either an oxidized 
or methoxylated C-ring under ESI-MS conditions. However, these 3 analogues do 
not appear to form a Zn2+ complex under the ESI-MS conditions. Complexes could 
not be observed for the rest of the analogues and that suggested that either those 
analogues do not form complexes under our experimental conditions, or that the 
complexes are not able to be detected by ESI-MS. 
 
 
Figure 37. ESI-MS showing formation of 3·Cu complex in 90% MeOH. 
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Figure 38. ESI-MS showing formation of 4·Cu complex in 90% MeOH, no complex 
formation with Zn2+ under our experimental conditions. 
 
 
Figure 39. ESI-MS showing formation of 5·Cu complex in 90% MeOH, no complex 
formation with Zn2+ under our experimental conditions. 
 
10291403 #5-41 RT: 0.07-0.51 AV: 37 NL: 7.98E4
T: FTMS + p ESI Full ms [100.00-1000.00]
360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
397.12
386.87
399.12
367.11 370.89 445.09386.19 437.66 451.67368.98 423.64
443.69429.67 457.70411.17 447.08400.12 435.24415.65371.10 452.18364.36 438.16 458.20393.21387.19381.26 430.17424.14
383.10
401.64
395.61
423.19376.90 440.70408.94360.92 391.28
419.11
10291403 #5-41 RT: 0.07-0.51 AV: 37 NL: 2.00E4
T: FTMS + p ESI Full ms [100.00-1000.00]
360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
367.11
370.89
368.98
369.11
371.10
364.36
366.37
360.27
368.11 373.21
366.18 367.20 371.90
365.10 376.90376.05360.92 368.16 370.62367.37 374.85371.16361.33 362.34 374.21 379.22376.32372.10369.99363.25
366.82
375.59 379.76377.20 380.68378.05
364.22 373.60
1003143 #5-29 RT: 0.07-0.46 AV: 25 NL: 2.47E4
T: FTMS + p ESI Full ms [100.00-1000.00]
450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600 610 620 630 640 650
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
579.03
514.06
499.03 565.05 609.04564.05
624.03580.04
581.03516.05501.03469.02 484.05
471.02 486.04 594.02
610.05566.06
625.03
617.01582.03502.12
595.02 640.06466.56 531.06 637.06517.06
568.06503.03487.05472.02 641.07
511.00
539.09525.11
482.00
597.02
576.03
583.03 628.06
498.11
550.03
604.16
560.15453.03
554.48
465.83
458.88
1003143 #6-32 RT: 0.08-0.51 AV: 27 NL: 2.35E4
T: FTMS + p ESI Full ms [100.00-1000.00]
570 572 574 576 578 580 582 584 586 588 590 592 594 596 598 600
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
579.03
577.04
580.04
578.04 581.03
594.02592.02
582.03 595.02593.03 596.02573.53
597.02576.03 583.03572.09 584.03 598.05571.62 600.04574.48 590.12
577.44
576.93
579.08
587.17
578.81
589.15 590.97585.33
N
N
N
Cu
Exact Mass: 367.11
L
N
N
OCH3
N
Cl
Cl
CH3
Cu
Exact Mass: 562.05
L
N
N
OCH3
N
Cl
Cl
CH3
Cu
OH
Exact Mass: 579.05
63 
 
DNA Binding activity of Pg and Tm analogues  
In order to determine the nature of interactions between DNA and the Pg and Tm 
analogues, the analogues were incubated with CT-DNA in the presence and 
absence of metal ions. The metal ions (Cu2+ and Zn2+) were included in order to 
assess if there was a difference in binding mode of the free analogue compared 
with metal complex, and also to compare binding modes of possible Cu2+ vs Zn2+ 
complexes that would be formed under the assay conditions. The binding was 
observed through changes in absorbance spectra. Red2 and compounds 1, 2, 3, 
5 and 6 are colored red but appear orange in the buffer at pH 7.8. These exhibited 
absorption bands in the visible region of the spectrum (450-650 nm).  The rest of 
the compounds were orange/yellow in methanol, but have no visible color in the 
pH 7.8 buffer and absorbed in the UV region (300-450 nm), except for compound 
10 that had no absorption peak in the UV-Vis spectrum at this pH. 
Figure 40 (top panel) shows the increase in absorption of red2 in the presence of 
increasing CT-DNA (0-80 µM) concentration. The hyperchromic effect observed 
was accompanied by a 13nm shift in λmax from 575 nm of free red2 to 562nm for 
red2 in the presence of DNA. When Cu2+ is added to red2 in the presence of 
varying concentrations of CT-DNA the same hyperchromic effect is observed at 
the absorption band at 534nm. These spectroscopic changes suggest an 
interaction between the ligand and the DNA that is not intercalation. These 
observations contrast those made for 1·Cu which intercalates into DNA, and 
suggests that, just like the free analogues, Cu2+ complexes of prodigiosins will bind  
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Figure 40. Spectral changes observed in the interaction of red2 with varying 
concentrations of CT-DNA in the absence (top panel) and presence  of 
Cu2+(middle panel) and Zn2+ (bottom panel). 
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DNA by mixed modes80. Our ESI-MS data suggests that a red2·Cu complex can 
form in situ which means the pyrrole ring nitrogens in the red2·Cu complex are not 
available for hydrogen bonding. Since we do not observe spectral changes 
expected for intercalation, this leaves electrostatic forces or groove binding as 
possible modes of interactions between red2·Cu complex and CT-DNA. 
In contrast, the presence of Zn2+ resulted in a 25% hypochromic shift accompanied 
by a 3nm red shift in the absorbance of red2 with varying concentrations of CT-
DNA. This observation suggests that the Zn2+ complex interacts with DNA by a 
stacking interaction such as intercalative binding mode. Bathochromic (red) shift 
and hypochromic effect are characteristic of intercalation84. 
Analogue 2 interacted with CT-DNA similar to what was observed with red2 with 
hyperchromic effect observed in the absence and presence of Cu2+ and 
hypochromic effect in the presence of Zn2+(figure 41). 
With the analogues 3, 5 and 6, hyperchromic effect accompanied by blue shift was 
observed in all the spectra of varying concentrations of CT-DNA with and without 
Cu2+ or Zn2+. This observation is consistent with ESI-MS data where no Zn2+ 
complex was observed so the DNA binding mode in the presence of Zn2+ would 
be expected to be similar to free 3. The hyperchromism observed in the presence 
of Cu2+ suggests that Cu2+ complexes formed in situ are not intercalating into DNA. 
Hyperchromism and blue shift suggest binding through external contact85.  
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Figure 41. Spectral changes observed in the interaction of 2 with varying 
concentrations of CT-DNA in the absence (top panel) and presence  of Cu2+ 
(middle panel) and Zn2+ (bottom panel). 
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Figure 42. Interaction of 3 with CT-DNA results in an increase in absorption of the 
prodigiosin analogue in the absence (top panel) and presence of Cu2+ (middle 
panel) and Zn2+ (bottom panel). 
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Figure 43. Interaction of 4 with CT-DNA results in a slight increase in absorption 
of the prodigiosin analogue in the absence (top panel) and no change in the 
presence of Zn2+ (bottom panel). 
 
Analogues 4, 5 and 6 also showed hyperchromic effect on addition of DNA in the 
absence of the metal ions. The interaction of 4 with DNA in the presence of Cu2+ 
could not be followed using UV-Vis as the UV-Vis signal was lost on addition of 
Cu2+. ESI-MS data suggests that 4 forms a complex with Cu so the lack of a UV-
vis signal suggests that the complex formed does not have a distinct UV-vis peak. 
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Figure 44. Interaction of 5 with CT-DNA results in an increase in absorption of the 
prodigiosin analogue in the absence (top panel) and presence of Cu2+ (middle 
panel) and Zn2+ (bottom panel). 
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Figure 45. Interaction of 6 with CT-DNA results in an increase in absorption of the 
prodigiosin analogue in the absence (top panel) and presence of Cu2+ (middle 
panel) and to a lesser extent Zn2+ (bottom panel). 
-0.1
-0.05
0
0.05
0.1
0.15
0.2
0.25
0.3
350 400 450 500 550 600 650
A
b
s
wavelength (nm)
0 µM
10 µM
20 µM
30 µM
40 µM
-0.01
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
400 450 500 550 600 650
A
b
s
wavelength (nm)
0 µM
10 µM
20 µM
40 µM
60 µM
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
400 450 500 550 600 650 700
A
b
s
wavelength (nm)
0 µM
5 µM
10 µM
20 µM
40 µM
71 
 
Analogue 7 does not appear to interact with DNA based on the UV-Vis experiment. 
Even in the presence of Cu2+ there was no change in the UV-vis spectra of 7 in 
varying concentrations of CT-DNA (figure 46). However, in the presence of Zn2+ a 
clear hyperchromic effect is observed suggesting that Zn2+ probably forms a 
complex that intercalates into DNA although this complex could not be observed 
in our ESI-MS experiments. 
We did not observe complex formation with analogue 8 under ESI-MS conditions. 
This situation is similar to that seen with compound 7. However, unlike 7, 8 does 
interact with DNA as seen by observed hypochromic shift in the UV-Vis 
absorbance spectra (figure 47). With addition of Cu2+ however, 8 loses the ability 
to interact with CT-DNA and addition of Zn2+ resulted in a hyperchromic shift in the 
absorbance. 
Analogue 9 interacts with CT-DNA resulting in an increase in absorbance of the 
analogue as concentration of DNA is increased both in the presence and absence 
of Zn2+(figure 48). In the presence of Cu2+ 9 loses its absorption peak, and there 
is no distinct peak to observe except for a shoulder around 370nm. However, there 
were no changes in absorbance observed in this shoulder.  
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Figure 46. Interaction of 7 with CT-DNA does not change the absorption of the 
prodigiosin analogue (300nm) in the absence (top panel) and presence of Cu2+ 
(middle panel). An increase in absorption is observed in the presence of Zn2+ 
(bottom panel). 
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Figure 47. Interaction of 8 with CT-DNA results in an increase in absorption of the 
prodigiosin analogue in the absence (top panel) and presence of Cu2+ (middle 
panel) and Zn2+ (bottom panel). 
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Figure 48. Interaction of 9 with CT-DNA results in an increase in absorption of the 
prodigiosin analogue in the absence (top panel) and presence of Zn2+ (bottom 
panel) and no change in absorbance with Cu2+ (middle panel). 
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Interaction of 10 with CT-DNA could not be determined by this method because 
the analogue did not have a UV-Vis signal. A summary of the observations from 
these experiments is shown in table 2: 
Table 2: Summary of observed UV-Vis spectral changes of prodigiosin and 
tambjamine analogues in the presence of 40 µM CT-DNA. 
 Free analogue Cu2+ Zn2+ 
 
red2 
13nm blue shift 
60% hyperchromicity 
no λmax shift 
19% hyperchromicity 
3nm red shift 
25% hypochromicity 
1 
 
no λmax shift 
28% hyperchromicity 
no λmax shift 
23% hypochromicity 
no λmax shift 
9% hyperchromicity 
 
2 
6nm blue shift 
50% hyperchromicity 
no λmax shift 
12% hyperchromicity 
no λmax shift 
47% hypochromicity 
 
3 
24nm blue shift 
30% hyperchromicity 
no λmax shift 
33% hyperchromicity 
7nm blue shift 
28% hyperchromicity 
 
4 
no λmax shift 
19% hyperchromicity 
no λmax shift 
- 
no λmax shift 
- 
 
5 
28nm blue shift 
32% hyperchromicity 
no λmax shift 
22% hyperchromicity 
no λmax shift 
17% hyperchromicity 
 
6 
11nm blue shift 
59 % hyperchromicity 
no λmax shift 
20% hyperchromicity 
no λmax shift 
8% hyperchromicity 
 
7 
no λmax shift 
- 
no λmax shift 
- 
no λmax shift 
28% hyperchromicity 
 
8 
14nm blue shift 
35% hypochromicity 
no λmax shift 
- 
no λmax shift 
43% hyperchromicity 
 
9 
6nm red shift 
15% hyperchromicity 
no λmax shift 
- 
no λmax shift 
31% hyperchromicity 
 
10 
 
No UV-Vis signal 
 
Percent hyper/hypochromicity (% H) was calculated using the equation;  
% H = 
ε ε
ε
∗ 100% 
Where εf and εb are the extinction coefficient of free and fully bound ligand. 
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As seen in table 2, the Pg and Tm analogues interact with DNA mainly through 
non intercalative binding modes, with the exception of red·Zn, 1·Cu, 1·Zn and 
compounds 8 and 9 where hypochromism was observed which suggests a 
stacking interaction. There was no trend observed that relates the mode of DNA 
binding to the structure of the analogues. 
 
DNA Cleavage 
Concentration Dependent DNA Cleavage 
The DNA cleavage activity of the Pg and Tm analogues in the presence of Cu2+ 
and Zn2+ was studied using supercoiled pUC19 plasmid DNA as a substrate under 
physiological conditions (pH 7.4, 37 °C) for 1 hr. In the presence of a DNA nuclease 
if only one strand is cleaved, the supercoiled form will relax to produce a nicked 
circular form, and a linear form will be produced if both strands are cleaved. These 
three plasmid DNA conformations were distinguishable when subjected to agarose 
gel electrophoresis.  
Figure 49 shows a representative gel from the concentration dependent cleavage 
of DNA by the analogues in the presence of Cu2+. 
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pUC19 + + + + + + + 
1 50 nM 100 nM 300 nM 500 nM 1 uM 2.5 5 µM 
Cu2+ + + + + + + + 
H2O2 + + + + + + + 
 
 
 
 
Figure 49. Gel shift analysis showing cleavage of pUC19 DNA in the presence of 
1 and added equimolar Cu2+ and 25 µM H2O2 at 37 °C.  
 
All the compounds in the presence of Cu2+ and H2O2 showed significant DNA 
cleavage activity in a concentration dependent manner. The gel shift analysis 
shown in figure 49 shows noticeable linear DNA from about 500 nM of 1 which 
increases as concentration of 1 increases up to 5 µM. At the same time the amount 
of form I DNA on the gel decreases as concentration of 1 increases confirming 
conversion of form I to form III. 
The linear DNA on the gels was quantified and is shown in figures 50-53. In the 
presence of Cu2+ and H2O2 there was a concentration-dependent increase in 
cleavage of supercoiled DNA to the linear form with increase in concentration of 
test compounds. 
Form II 
Form III 
 
Form I 
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Figure 50. DNA linearization with increasing concentration of Red2. 
 
 
Figure 51. DNA linearization with increasing concentration of 4. 
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Figure 52. DNA linearization with increasing concentration of 7. 
 
 
Figure 53. DNA linearization with increasing concentration of 10. 
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The representative plots in figures 50-53 are for a natural prodigiosin (red2), 
prodigiosin analogues (4, 10), a tambjamine analogue (7). Although we observed 
a concentration dependent increase in linearization, we also came to the 
conclusion that observing the end point, after a one hour incubation, would limit 
the information that can be gained from linearization experiments as there was no 
significant difference among the analogues in the amount of DNA converted to 
linear form. This led to the time dependent experiments in an effort to determine if 
there were any differences in their activities. 
 
Time Dependent DNA Linearization 
Time dependent DNA cleavage was studied using supercoiled pUC19 DNA. 
Representative gels from time dependent linearization of supercoiled DNA are 
shown in figures 54 and 55. An examination of the gels showed that the cleavage 
of DNA is time dependent and an interesting feature observed in all the gels was 
the occurrence of form II DNA from time = 0 min. However there was no increase 
in form III DNA until at least time = 20 min with significant form III DNA observed 
at 20 min. This suggests a delayed reaction, i.e. a two-step process, with the slow 
step being the rate determining step and concentration dependent. Analysis of the 
gels (Figures 54 and 55) also suggests that the compounds are able to perform 
successive single strand cleavage as well as direct double strand cleavage as 
evidenced by the presence of form II DNA from time = 0 min but not form III DNA 
which only becomes visible on the gels at time = 20 min suggesting that the 
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linearization of DNA does not necessarily go in the order supercoiled → open 
circular → linear as previously suggested in figure 31. In addition the observation 
of a single, well defined linear DNA band on the gel suggests that the cleavage of 
DNA is not a random process because random cleavage would be expected to 
produce multiple bands or a smear of linear DNA fragments. 
The data from time dependent linearization of supercoiled to form III in the assays 
containing Cu(OAc)2 was plotted as a function of time and is shown by the 
representative plots in figures  56-57.  
DNA cleavage reactions with Zn2+ under physiological conditions showed no 
linearization of DNA with concentrations of both Zn2+ and analogue of up to 20 µM 
(8 times the concentration used for cleavage with Cu2+) (Figure 56). This 
observation suggests that any Zn2+ complexes formed merely bind to DNA as 
indicated by UV-vis data but do not cleave DNA. 
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Figure 54. Ethidium bromide stained agarose gel showing time dependent 
cleavage of supercoiled pUC19 DNA (8.5 nM). In a reaction containing 2.5 µM 6, 
2.5 µM Cu(OAc)2 and 25 µM H2O2. 
 
                  
Figure 55. Ethidium bromide stained agarose gel showing time dependent 
cleavage of supercoiled pUC19 DNA (8.5 nM). In a reaction containing 2.5 µM 10, 
2.5 µM Cu(OAc)2 and 25 µM H2O2. 
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 Compound 4 Compound 3 
 2.5 µM 5.0 µM 10 µM 20 µM 2.5 µM 5.0 µM 10 µM 20 µM 
pUC19 + + + + + + + + 
Zn2+ + + + + + + + + 
H2O2 + + + + + + + + 
                 
Figure 56. Representative ethidium bromide stained agarose gel showing pUC19 
DNA in a reaction containing increasing concentrations of 4 (lanes1-4) and 3 lanes 
(5-8) with equimolar concentrations of Zn(OAc)2 and 25 µM H2O2. 
 
Analysis of the data revealed that linearization of DNA by prodigiosin and 
tambjamine analogues in the presence of Cu2+ is a two-step process. The gel shift 
data suggests that the reaction has a slow and fast step that likely involves a slow 
binding step to DNA which is concentration dependent and a fast nicking step of 
SC DNA to either form II or form III but does not seem to necessarily go through 
relaxation of supercoiled DNA (form I) to nicked or OC DNA (form II) followed 
linearization to form III.  

       →         →    
  
                                                                                               
   
   k1            
                                                       k2 
84 
 
Where k1 and k2 are rate constants for the first and second steps. If k2 >> k1, k1 
being the slow step becomes the rate determining step and the rate of cleavage of 
DNA becomes independent of k2.  
The rate constant for the linearization of DNA can be determined from fitting to the 
equation:  y = Ao(1-e-k1t). 
 
 
Figure 57. Time dependent pUC19 DNA cleavage with corresponding 
kaleidagraph plot for red2. 
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The red2 data fit poorly to the first order reaction model and was therefore fit to a 
linear equation with the rate of linearization for red2 being determined from the 
slope of the linear equation. This is in contrast to what was observed for the rest 
of the compounds in which an initial lag was observed in the formation of form III 
DNA (Figure 58), although an intermediate form II DNA was present. As with red2, 
these observations suggest a two-step process except that in the case of 
compounds 1-10, the first event is a slow step and the subsequent step is much 
faster (k2>>k1). The initial lag phase likely corresponds to the DNA binding step or 
the first cleavage event as the lag was still observed when the compounds were 
preincubated with Cu2+ for 30 mins before addition of plasmid DNA (data not 
shown). However, the appearance of form II during this initial lag phase suggests 
that the conversion of form II DNA to form III DNA is not the fast step as we would 
expect to see form II DNA decreasing significantly while form III DNA increases. 
However, this is not apparent on the gels and suggests that both single and direct 
double strand scission are occurring simultaneously.  
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Figure 58. Time dependent pUC19 DNA cleavage with corresponding 
Kaleidagraph plot for 8 (top panel) and 10 (bottom panel). 
 
Figure 59 shows a representative plot the effect of ionic strength on DNA 
linearization. These experiments were carried out in the same buffer containing 
either 50 mM or 100 mM NaCl. As expected, the higher ionic strength led to 
decreased conversion of supercoiled DNA to linear form (Table 3). This is due to 
the stabilizing effect of the salt on DNA making the DNA backbone less accessible 
to the PgCu complexes.  
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Figure 59. Effect of increasing ionic strength on rate of DNA linearization by red2. 
 
Table 3. Rate constants of DNA linearization 
 50mM NaCl  100mM NaCl  
compound klin (min-1) stdev klin (1)/klin klin (min-1) stdev klin (1)/klin 
1 0.0127 0.0008 1 0.0035 0.0003 1 
2 0.0097 0.0008 1.3 0.0013 0.0001 2.7 
3 0.0094 0.0004 1.4 ND*   
4 0.0166 0.0014 0.8 0.0032 0.0003 1.1 
5 0.0112 0.0006 1.1 ND*   
6 0.0137 0.0007 0.9 0.0042 0.0002 0.8 
7 0.0153 0.0006 0.8 0.0034 0.00008 1 
8 0.0064 0.0003 1.9 0.0027 0.00009 1.3 
9 0.0041 0.0002 3.1 ND*   
10 0.0164 0.0008 0.8 0.0025 0.0001 1.4 
*data fit to linear equation. 
 klin = rate constant of DNA linearization 
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The rate constants for DNA linearization are shown in table 3 and expressed as 
min-1. These rate constants are determined by the slow step which is the binding 
step and so reflect the rate of metal complex binding to DNA. The rates were 
essentially similar except for compounds 8 and 9, both tambjamines with -OMe 
group substituted with small alkyl groups, which were  ̴ 2-3 fold faster in the lower 
(50 mM) ionic strength buffer.  
 
Discussion and Conclusion 
Both natural and synthetic prodigiosins and tambjamines have a wide variety of 
biological activities. We measured the pKa of the analogues and looked at their 
metal binding properties. The data indicate very small changes in pKa which made 
it difficult to discern any useful relationship between pKa and structure and 
suggests that the substituents on the pyrrole rings of these compounds had very 
little effect on their ionization potential. The prodigiosins and tambjamines have 
been shown to interact with DNA and cause DNA cleavage. The ability of these 
compounds to mediate DNA cleavage can help to explain some of their biological 
activity. Double-stranded DNA cleavage cannot be easily repaired and is therefore 
more desired from the standpoint of anti-cancer drug development for any DNA-
cleaving metal complex. Our analogues showed mixed modes of DNA binding, not 
related to their structure; the different binding modes observed with red2·Cu and 
1·Cu in particular were unexpected since the difference in these 2 compounds (the 
C-ring substituents) is not expected to affect their planarity. In addition all the 
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analogues showed efficient DNA cleavage in the presence of Cu2+ regardless of 
the observed DNA interaction by UV-Vis experiment suggesting that mode of 
binding does not determine cleavage activity. The cleavage of DNA was both 
concentration and time dependent  with an initial lag phase suggesting a two-step 
process; a PgCu-DNA binding step followed by the cleavage reaction. The 
absence of smearing or fragments of linear DNA on the agarose gels suggests 
that there is a single linear cleavage product suggesting that the complexes only 
perform a single cut. Furthermore, we have proposed that the lag phase observed 
in the cleavage experiments is due to the binding of the complex to DNA and this 
could explain the lack of other fragments of linear DNA as the experiments where 
only carried out over one hour and so additional cleavage events would require 
another binding event which is slow and would not be observable in the time that 
the experiment was conducted. Experiments with ssDNA showed that these 
compounds do not cleave ssDNA (data not shown) suggesting that they require 
some secondary structure for cleavage activity. It is interesting to note that the UV-
Vis DNA binding data suggested that the compounds interact with DNA mostly by 
groove binding in dsDNA. Single stranded DNA does not adopt a helical formation 
and this is further support of our explanation as to why we did not observe any 
cleavage of ssDNA. Based on these observations we propose a revised model for 
cleavage of DNA in figure 60 below; 
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Figure 60. Revised model for the cleavage of DNA by prodigiosin and tambjamine 
analogues in the presence of Cu2+. The slow binding event is followed by fast 
cleavage events of either a single nick (A) or direct double strand cleavage (B). 
 
 There was no cleavage activity was observed with Zn2+. Since Zn2+ is redox 
inactive this observation was not unexpected even though there are some reports 
that have implicated Zn2+ in DNA damage through a hydrolytic mechanism86,87. In 
chapter 2 we proposed a mechanism for generation of a Pg–Cu–OOH complex 
able to cause the DNA damage either directly by attack on the phosphate group 
on the DNA backbone or through generation of a short-lived hydroxyl radical (fig 
29). The data suggests that either concentration of Pg or Tm is limiting or that the 
Pg/Tm metal complex once bound to DNA is not released since we did not observe 
smaller fragments of linear DNA suggesting that there is one cleavage event on 
both strands. However, despite the DNA cleavage activity of prodigiosin and 
tambjamine analogues in the presence of Cu2+ and H2O2 there was no trend 
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observed between the structure of the analogues and DNA cleavage activity. 
Recent data shows that these compounds have markedly different antimalarial 
activities17,64. The DNA cleavage data also did not correlate with antimalarial 
activity of these compounds and this suggests the antimalarial activity is not 
through Cu2+ mediated DNA cleavage by Pg and Tm compounds. However, the 
fact that these compounds cause dsDNA damage raises concerns on their 
suitability for use in treatment of diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
References 
 
1. D'Addario, G.; Pintilie, M.; Leighl, N. B.; Feld, R.; Cerny, T.; Shepherd, F. A., 
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell 
lung cancer: a meta-analysis of the published literature. In J Clin Oncol, United States, 
2005; Vol. 23, pp 2926-36. 
2. Chen, J.; Yin, J.; Li, X.; Wang, Y.; Zheng, Y.; Qian, C.; Xiao, L.; Zou, T.; Wang, Z.; Liu, 
J.; Zhang, W.; Zhou, H.; Liu, Z., WISP1 polymorphisms contribute to platinum-based 
chemotherapy toxicity in lung cancer patients. In Int J Mol Sci, Switzerland, 2014; Vol. 15, 
pp 21011-27. 
3. Hoeijmakers, J. H., DNA damage, aging, and cancer. In N Engl J Med, United States, 
2009; Vol. 361, pp 1475-85. 
4. Ciccia, A.; Elledge, S. J., The DNA damage response: making it safe to play with 
knives. In Mol Cell, 2010 Elsevier Inc: United States, 2010; Vol. 40, pp 179-204. 
5. Liu, P.; Wang, Y.-y.; Qi, X.; Gu, Q.; Geng, M.; Li, J., Undecylprodigiosin Induced 
Apoptosis in P388 Cancer Cells Is Associated with Its Binding to Ribosome. PLoS ONE 2013, 
8 (6), e65381. 
6. Pandey, R.; Chander, R.; Sainis, K. B., Prodigiosins as anti cancer agents: living upto 
their name. Curr Pharm Des 2009, 15 (7), 732-41. 
7. Pérez-Tomás, R.; Montaner, B.; Llagostera, E.; Soto-Cerrato, V., The prodigiosins, 
proapoptotic drugs with anticancer properties. Biochemical Pharmacology 2003, 66 (8), 
1447-1452. 
8. Williamson, N. R.; Fineran, P. C.; Leeper, F. J.; Salmond, G. P., The biosynthesis and 
regulation of bacterial prodiginines. Nat Rev Microbiol 2006, 4 (12), 887-99. 
9. Williamson, N. R., Chawrai, S., Leeper, F. J. and Salmond, G. P. C., Prodiginines and 
Their Potential Utility as Proapoptotic Anticancer Agents,  in Emerging Cancer Therapy 
(eds A. M. Fialho and A. M. Chakrabarty). John Wiley & Sons, Inc.: Hoboken, New Jersey, 
2010. 
10. Castro, A.; Deck, J.; Hugo, M.; Williams, L.; Zingg, M., Notes. Prodigiosin 
Hydrochloride. The Journal of Organic Chemistry 1958, 23 (8), 1232-1233; Castro, A. J.; 
Deck, J. F.; Hugo, M. T.; Lowe, E. J.; Marsh, J. P.; Pfeiffer, R. J., Prodigiosin1a. The Journal 
of Organic Chemistry 1963, 28 (3), 857-860. 
11. O'Brien, S. M.; Claxton, D. F.; Crump, M.; Faderl, S.; Kipps, T.; Keating, M. J.; Viallet, 
J.; Cheson, B. D., Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-
Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 
2009, 113 (2), 299-305; Paik, P. K.; Rudin, C. M.; Pietanza, M. C.; Brown, A.; Rizvi, N. A.; 
Takebe, N.; Travis, W.; James, L.; Ginsberg, M. S.; Juergens, R.; Markus, S.; Tyson, L.; 
Subzwari, S.; Kris, M. G.; Krug, L. M., A phase II study of obatoclax mesylate, a Bcl-2 
antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011, 74 (3), 
481-5. 
93 
 
12. Papireddy, K.; Smilkstein, M.; Kelly, J. X.; Shweta; Salem, S. M.; Alhamadsheh, M.; 
Haynes, S. W.; Challis, G. L.; Reynolds, K. A., Antimalarial activity of natural and synthetic 
prodiginines. J Med Chem 2011, 54 (15), 5296-306. 
13. Jenkins, S.; Incarvito, C. D.; Parr, J.; Wasserman, H. H., Structural studies of C-ring 
substituted unnatural analogues of prodigiosin. CrystEngComm 2009, 11 (2), 242-245. 
14. Azuma, T.; Watanabe, N.; Yagisawa, H.; Hirata, H.; Iwamura, M.; Kobayashi, Y., 
Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin 
hydrochloride, a novel immunosuppressant. Immunopharmacology 2000, 46 (1), 29-37. 
15. Han, S. B.; Kim, H. M.; Kim, Y. H.; Lee, C. W.; Jang, E.-S.; Son, K. H.; Kim, S. U.; Kim, 
Y. K., T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. 
International Journal of Immunopharmacology 1998, 20 (1–3), 1-13. 
16. Isaka, M.; Jaturapat, A.; Kramyu, J.; Tanticharoen, M.; Thebtaranonth, Y., Potent 
in vitro antimalarial activity of metacycloprodigiosin isolated from Streptomyces 
spectabilis BCC 4785. Antimicrob Agents Chemother 2002, 46 (4), 1112-3. 
17.  . 
18. Seganish, J. L.; Davis, J. T., Prodigiosin is a chloride carrier that can function as an 
anion exchanger. Chem Commun (Camb) 2005,  (46), 5781-3. 
19. Gale, P. A.; Light, M. E.; McNally, B.; Navakhun, K.; Sliwinski, K. E.; Smith, B. D., Co-
transport of H+/Cl- by a synthetic prodigiosin mimic. Chem Commun (Camb) 2005,  (30), 
3773-5. 
20. Melvin, M. S.; Calcutt, M. W.; Noftle, R. E.; Manderville, R. A., Influence of the a-
ring on the redox and nuclease properties of the prodigiosins: importance of the bipyrrole 
moiety in oxidative DNA cleavage. Chem Res Toxicol 2002, 15 (5), 742-8. 
21. Harris, A. K.; Williamson, N. R.; Slater, H.; Cox, A.; Abbasi, S.; Foulds, I.; Simonsen, 
H. T.; Leeper, F. J.; Salmond, G. P., The Serratia gene cluster encoding biosynthesis of the 
red antibiotic, prodigiosin, shows species- and strain-dependent genome context 
variation. Microbiology 2004, 150 (Pt 11), 3547-60. 
22. Pinkerton, D. M.; Banwell, M. G.; Garson, M. J.; Kumar, N.; de Moraes, M. O.; 
Cavalcanti, B. C.; Barros, F. W. A.; Pessoa, C., Antimicrobial and Cytotoxic Activities of 
Synthetically Derived Tambjamines C and E – J, BE-18591, and a Related Alkaloid from the 
Marine Bacterium Pseudoalteromonas tunicata. 
23. Borah, S.; Melvin, M. S.; Lindquist, N.; Manderville, R. A., Copper-mediated 
nuclease activity of a tambjamine alkaloid. Journal of the American Chemical Society 1998, 
120 (19), 4557-4562. 
24. Melvin, M. S.; Tomlinson, J. T.; Park, G.; Day, C. S.; Saluta, G. R.; Kucera, G. L.; 
Manderville, R. A., Influence of the a-ring on the proton affinity and anticancer properties 
of the prodigiosins. Chem Res Toxicol 2002, 15 (5), 734-41. 
25. Park, G.; Tomlinson, J. T.; Melvin, M. S.; Wright, M. W.; Day, C. S.; Manderville, R. 
A., Zinc and copper complexes of prodigiosin: implications for copper-mediated double-
strand DNA cleavage. Org Lett 2003, 5 (2), 113-6. 
94 
 
26. van Dam, L.; Levitt, M. H., BII Nucleotides in the B and C Forms of Natural-
sequence Polymeric DNA: A New Model for the C Form of DNA. Journal of Molecular 
Biology 2000, 304 (4), 541-561. 
27. www.genome.gov, 2013. 
28. Lu, X. J.; Olson, W. K., 3DNA: a software package for the analysis, rebuilding and 
visualization of three-dimensional nucleic acid structures. Nucleic Acids Research 2003, 
31 (17), 5108-5121. 
29. Bacolla, A.; Wells, R. D., Non-B DNA conformations, genomic rearrangements, and 
human disease. In J Biol Chem, United States, 2004; Vol. 279, pp 47411-4. 
30. Li, H. H.; Aubrecht, J.; Fornace, A. J., Toxicogenomics: overview and potential 
applications for the study of non-covalent DNA interacting chemicals. Mutat Res 2007, 
623 (1-2), 98-108. 
31. Mariappan, M.; Suenaga, M.; Mukhopadhyay, A.; Raghavaiah, P.; Maiya, B. G., 
Synthesis, structure, DNA binding and photocleavage activity of a ruthenium(II) complex 
with 11-(9-acridinyl)dipyrido[3,2-a:2′,3′-c]phenazine ligand. Inorganica Chimica Acta 
2011, 376 (1), 340-349. 
32. Hawkins, C. A.; Watson, C.; Yan, Y.; Gong, B.; Wemmer, D. E., Structural analysis of 
the binding modes of minor groove ligands comprised of disubstituted benzenes. Nucleic 
Acids Res 2001, 29 (4), 936-42. 
33. Xu, H.; Zheng, K.-C.; Chen, Y.; Li, Y.-Z.; Lin, L.-J.; Li, H.; Zhang, P.-X.; Ji, L.-N., Effects 
of ligand planarity on the interaction of polypyridyl Ru(ii) complexes with DNA. Dalton 
Transactions 2003,  (11), 2260-2268. 
34. Xu, H.; Zheng, K. C.; Lin, L. J.; Li, H.; Gao, Y.; Ji, L. N., Effects of the substitution 
positions of Br group in intercalative ligand on the DNA-binding behaviors of Ru(II) 
polypyridyl complexes. J Inorg Biochem 2004, 98 (1), 87-97. 
35. Hajian, R.; Guan Huat, T., Spectrophotometric Studies on the Thermodynamics of 
the ds-DNA Interaction with Irinotecan for a Better Understanding of Anticancer Drug-
DNA Interactions. Journal of Spectroscopy 2013, 2013, 8. 
36. Sirajuddin, M.; Haider, A.; Ali, S., Analytical Techniques For The Study Of Drug-DNA 
Interactions. International Journal 2013, 1 (9), 499-509. 
37. Palchaudhuri, R.; Hergenrother, P. J., DNA as a target for anticancer compounds: 
methods to determine the mode of binding and the mechanism of action. Curr Opin 
Biotechnol 2007, 18 (6), 497-503. 
38. Frederickson, C. J.; Koh, J. Y.; Bush, A. I., The neurobiology of zinc in health and 
disease. In Nat Rev Neurosci, England, 2005; Vol. 6, pp 449-62. 
39. Cowan, J. A., Chemical nucleases. Current Opinion in Chemical Biology 2001, 5 (6), 
634-642. 
40. Liu, C.; Wang, M.; Zhang, T.; Sun, H., DNA hydrolysis promoted by di- and multi-
nuclear metal complexes. Coordination Chemistry Reviews 2004, 248 (1–2), 147-168. 
41. Keck MV, L. S., Unwinding of supercoiled DNA by platinum-ethidium related 
complexes. 1992, 14. 
95 
 
42. Zhang, C. X.; Lippard, S. J., New metal complexes as potential therapeutics. Current 
Opinion in Chemical Biology 2003, 7 (4), 481-489. 
43. Kellett, A.; Howe, O.; O'Connor, M.; McCann, M.; Creaven, B. S.; McClean, S.; 
Foltyn-Arfa Kia, A.; Casey, A.; Devereux, M., Radical-induced DNA damage by cytotoxic 
square-planar copper(II) complexes incorporating o-phthalate and 1,10-phenanthroline 
or 2,2′-dipyridyl. Free Radical Biology and Medicine 2012, 53 (3), 564-576. 
44. Wu JC, K. J. a. S. J., Mechanism of Bleomycin: evidence for a rate determining 4' 
hydrogen abstraction from poly(dA-dU) associated with the formation of both free base 
and base propenal. 1985, 24. 
45. Cooke, M. S.; Evans, M. D.; Dizdaroglu, M.; Lunec, J., Oxidative DNA damage: 
mechanisms, mutation, and disease. FASEB J 2003, 17 (10), 1195-214. 
46. Kehrer, J. P., The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 
2000, 149 (1), 43-50. 
47. Sharma, P.; Jha, A. B.; Dubey, R. S.; Pessarakli, M., Reactive Oxygen Species, 
Oxidative Damage, and Antioxidative Defense Mechanism in Plants under Stressful 
Conditions. Journal of Botany 2012, 2012, 26. 
48. Lord, C. J.; Ashworth, A., The DNA damage response and cancer therapy. Nature 
2012, 481 (7381), 287-94. 
49. Wiseman, H.; Halliwell, B., Damage to DNA by reactive oxygen and nitrogen 
species: role in inflammatory disease and progression to cancer. Biochem J 1996, 313 ( Pt 
1), 17-29. 
50. Turrens, J. F., Mitochondrial formation of reactive oxygen species. The Journal of 
Physiology 2003, 552 (2), 335-344. 
51. Burdon, R. H., Superoxide and hydrogen peroxide in relation to mammalian cell 
proliferation. In Free Radic Biol Med, United States, 1995; Vol. 18, pp 775-94. 
52. Goustin, A. S.; Leof, E. B.; Shipley, G. D.; Moses, H. L., Growth factors and cancer. 
Cancer Res 1986, 46 (3), 1015-29. 
53. López-Lázaro, M., Dual role of hydrogen peroxide in cancer: Possible relevance to 
cancer chemoprevention and therapy. Cancer Letters 2007, 252 (1), 1-8. 
54. Droge, W., Free radicals in the physiological control of cell function. Physiol Rev 
2002, 82 (1), 47-95. 
55. Angele-Martinez, C.; Goodman, C.; Brumaghim, J., Metal-mediated DNA damage 
and cell death: mechanisms, detection methods, and cellular consequences. Metallomics 
2014, 6 (8), 1358-81. 
56. Ding, X.; Xie, H.; Kang, Y. J., The significance of copper chelators in clinical and 
experimental application. The Journal of Nutritional Biochemistry 2011, 22 (4), 301-310. 
57. Cobine, P. A.; Pierrel, F.; Winge, D. R., Copper trafficking to the mitochondrion and 
assembly of copper metalloenzymes. Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research 2006, 1763 (7), 759-772. 
58. Zhu, Z.; Labbé, S.; Peña, M. M. O.; Thiele, D. J., Copper Differentially Regulates the 
Activity and Degradation of Yeast Mac1 Transcription Factor. Journal of Biological 
Chemistry 1998, 273 (3), 1277-1280. 
96 
 
59. Macomber, L.; Rensing, C.; Imlay, J. A., Intracellular Copper Does Not Catalyze the 
Formation of Oxidative DNA Damage in Escherichia coli. Journal of Bacteriology 2007, 189 
(5), 1616-1626. 
60. Ruiz, R.; García, B.; Garcia-Tojal, J.; Busto, N.; Ibeas, S.; Leal, J. M.; Martins, C.; 
Gaspar, J.; Borrás, J.; Gil-García, R.; González-Alvarez, M., Biological assays and 
noncovalent interactions of pyridine-2-carbaldehyde thiosemicarbazonecopper(II) drugs 
with [poly(dA-dT)](2), [poly(dG-dC)] (2), and calf thymus DNA. J Biol Inorg Chem 2010, 15 
(4), 515-32. 
61. Jun, T.; Bochu, W.; Liancai, Z., Hydrolytic cleavage of DNA by quercetin zinc(II) 
complex. Bioorganic & Medicinal Chemistry Letters 2007, 17 (5), 1197-1199. 
62. Wang, X.-Y.; Zhang, J.; Li, K.; Jiang, N.; Chen, S.-Y.; Lin, H.-H.; Huang, Y.; Ma, L.-J.; 
Yu, X.-Q., Synthesis and DNA cleavage activities of mononuclear macrocyclic polyamine 
zinc(II), copper(II), cobalt(II) complexes which linked with uracil. Bioorganic & Medicinal 
Chemistry 2006, 14 (19), 6745-6751. 
63. An, Y.; Lin, Y. Y.; Wang, H.; Sun, H. Z.; Tong, M. L.; Ji, L. N.; Mao, Z. W., Cleavage of 
double-strand DNA by zinc complexes of dicationic 2,2'-dipyridyl derivatives. Dalton Trans 
2007,  (12), 1250-4. 
64. Kancharla, P.; Lu, W.; Salem, S. M.; Kelly, J. X.; Reynolds, K. A., Stereospecific 
Synthesis of 23-Hydroxyundecylprodiginines and Analogues and Conversion to 
Antimalarial Premarineosins via a Rieske Oxygenase Catalyzed Bicyclization. The Journal 
of Organic Chemistry 2014, 79 (23), 11674-11689. 
65. Diaz, R. I.; Regourd, J.; Santacroce, P. V.; Davis, J. T.; Jakeman, D. L.; Thompson, A., 
Chloride anion transport and copper-mediated DNA cleavage by C-ring functionalized 
prodigiosenes. Chem Commun (Camb) 2007,  (26), 2701-3. 
66. Melvin, M. S.; Wooton, K. E.; Rich, C. C.; Saluta, G. R.; Kucera, G. L.; Lindquist, N.; 
Manderville, R. A., Copper-nuclease efficiency correlates with cytotoxicity for the 4-
methoxypyrrolic natural products. J Inorg Biochem 2001, 87 (3), 129-35. 
67. Tisato, F.; Marzano, C.; Porchia, M.; Pellei, M.; Santini, C., Copper in diseases and 
treatments, and copper-based anticancer strategies. Med Res Rev 2010, 30 (4), 708-49. 
68. Barry, N. P.; Edafe, F.; Therrien, B., Anticancer activity of tetracationic arene 
ruthenium metalla-cycles. Dalton Trans 2011, 40 (27), 7172-80. 
69. Keck, M. V.; Lippard, S. J., Unwinding of supercoiled DNA by platinum-ethidium 
and related complexes. Journal of the American Chemical Society 1992, 114 (9), 3386-
3390. 
70. Milacic, V.; Chen, D.; Giovagnini, L.; Diez, A.; Fregona, D.; Dou, Q. P., Pyrrolidine 
dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by 
inhibiting the proteasomal activity(). Toxicology and applied pharmacology 2008, 231 (1), 
24-33. 
71. Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, 
B. K., From bench to bedside--preclinical and early clinical development of the anticancer 
agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J 
Inorg Biochem 2006, 100 (5-6), 891-904. 
97 
 
72. Regourd, J.; Al-Sheikh Ali, A.; Thompson, A., Synthesis and Anti-Cancer Activity of 
C-Ring-Functionalized Prodigiosin Analogues. Journal of Medicinal Chemistry 2007, 50 (7), 
1528-1536. 
73. Dairi, K.; Tripathy, S.; Attardo, G.; Lavallée, J.-F., Two-step synthesis of the 
bipyrrole precursor of prodigiosins. Tetrahedron Letters 2006, 47 (15), 2605-2606. 
74. Heaton, P. a. K., JT, DNA Quantification. In Essentials of Nucleic Acid Analysis, Keer, 
J. a. B., L, Ed. Royal Society of Chemistry: Cambridge, 2008; pp 83-100. 
75. Carbone, A.; Fioretti, F. M.; Fucci, L.; Ausió, J.; Piscopo, M., High efficiency method 
to obtain supercoiled DNA with a commercial plasmid purification kit. Acta Biochim Pol 
2012, 59 (2), 275-8. 
76. Ameta, R. K.; Singh, M.; Kale, R. K., Synthesis and structure-activity relationship of 
benzylamine supported platinum(iv) complexes. New Journal of Chemistry 2013, 37 (5), 
1501-1508. 
77. Manderville, R. A.; Wade Calcutt, M.; Dai, J.; Park, G.; Gillman, I. G.; Noftle, R. E.; 
Mohammed, A. K.; Birincioglu, M.; Dizdaroglu, M.; Rodriguez, H.; Akman, S. A., 
Stoichiometric preference in copper-promoted oxidative DNA damage by ochratoxin A. J 
Inorg Biochem 2003, 95 (2-3), 87-96. 
78. Rajarajeswari, C.; Ganeshpandian, M.; Palaniandavar, M.; Riyasdeen, A.; Akbarsha, 
M. A., Mixed ligand copper(II) complexes of 1,10-phenanthroline with tridentate 
phenolate/pyridyl/(benz)imidazolyl Schiff base ligands: covalent vs non-covalent DNA 
binding, DNA cleavage and cytotoxicity. J Inorg Biochem 2014, 140, 255-68. 
79. LePecq, J. B.; Paoletti, C., A fluorescent complex between ethidium bromide and 
nucleic acids. Physical-chemical characterization. In J Mol Biol, England, 1967; Vol. 27, pp 
87-106. 
80. Melvin, M. S.; Ferguson, D. C.; Lindquist, N.; Manderville, R. A., DNA Binding by 4-
Methoxypyrrolic Natural Products. Preference for Intercalation at AT Sites by Tambjamine 
E and Prodigiosin. J Org Chem 1999, 64 (18), 6861-6869. 
81. Chang, T. M.; Sinharay, S.; Astashkin, A. V.; Tomat, E., Prodigiosin analogue 
designed for metal coordination: stable zinc and copper pyrrolyldipyrrins. Inorg Chem 
2014, 53 (14), 7518-26. 
82. Cusumano, M.; Di Pietro, M. L.; Giannetto, A.; Nicolo, F.; Rotondo, E., Noncovalent 
Interactions of Platinum(II) Square Planar Complexes Containing Ligands Out-of-Plane 
with DNA. In Inorg Chem, 1998; Vol. 37, pp 563-568. 
83. Lippard, S. J., Platinum complexes: probes of polynucleotide structure and 
antitumor drugs. Accounts of Chemical Research 1978, 11 (5), 211-217. 
84. Shahabadi, N.; Kashanian, S.; Mahdavi, M.; Sourinejad, N., DNA Interaction and 
DNA Cleavage Studies of a New Platinum(II) Complex Containing Aliphatic and Aromatic 
Dinitrogen Ligands. Bioinorg Chem Appl 2011, 2011, 525794. 
85. Gupta, R. K.; Pandey, R.; Sharma, G.; Prasad, R.; Koch, B.; Srikrishna, S.; Li, P. Z.; Xu, 
Q.; Pandey, D. S., DNA binding and anti-cancer activity of redox-active heteroleptic piano-
stool Ru(II), Rh(III), and Ir(III) complexes containing 4-(2-
methoxypyridyl)phenyldipyrromethene. Inorg Chem 2013, 52 (7), 3687-98. 
98 
 
86. Sheng, X.; Guo, X.; Lu, X. M.; Lu, G. Y.; Shao, Y.; Liu, F.; Xu, Q., DNA binding, 
cleavage, and cytotoxic activity of the preorganized dinuclear zinc(II) complex of 
triazacyclononane derivatives. Bioconjug Chem 2008, 19 (2), 490-8. 
87. Sissi, C.; Mancin, F.; Palumbo, M.; Scrimin, P.; Tecilla, P.; Tonellato, U., DNA 
phosphodiester bond hydrolysis mediated by Cu(II) and Zn(II) complexes of 1,3,5,-
triamino-cyclohexane derivatives. Nucleosides Nucleotides Nucleic Acids 2000, 19 (8), 
1265-71. 
88. Melvin, M. S.; Tomlinson, J. T.; Saluta, G. R.; Kucera, G. L.; Lindquist, N.; 
Manderville, R. A., Double-Strand DNA Cleavage by Copper·Prodigiosin. Journal of the 
American Chemical Society 2000, 122 (26), 6333-6334. 
89. Boger, D. L.; Patel, M., Total synthesis of prodigiosin, prodigiosene, and 
desmethoxyprodigiosin: Diels-Alder reactions of heterocyclic azadienes and development 
of an effective palladium(II)-promoted 2,2'-bipyrrole coupling procedure. The Journal of 
Organic Chemistry 1988, 53 (7), 1405-1415. 
90. D'Alessio, R.; Bargiotti, A.; Carlini, O.; Colotta, F.; Ferrari, M.; Gnocchi, P.; Isetta, 
A.; Mongelli, N.; Motta, P.; Rossi, A.; Rossi, M.; Tibolla, M.; Vanotti, E., Synthesis and 
immunosuppressive activity of novel prodigiosin derivatives. In J Med Chem, United 
States, 2000; Vol. 43, pp 2557-65. 
 
